yea i understand that but i thought at first that the end goal is that they decrease e2 in my body but through different routes u get me but now ur telling me that aromasin wont give the same effect as letro and anastrozole
yea i got it now do u hvae a source that sells letrozolejust send me a dm and ERα signaling is absent or blocked, growth plates can stay open much longer. u get it now thats why letrzole is a better option
bro obc they dont givbe the same effecrts
Heightmaxing Guide 101
Thread song:
ive been studying this topic since i learned about it and i have ordered my stack and everything is ready enough about that though tho. In this thread I will go through a couple of things like growth plates, HGH, AIs, AAS, FGFR inhibitors, and more. Some of the topics I will talk about are pretty new knowledge so don't bash on me if I am wrong cuz I'm trying my bestand first post back after my banishment for 4 days for a crime i did not commit
but i have collected alot of knowledge so i hope u guys will rep this and help me fix my rep to post ratio thanks bhai!
This thread is for educational and harm reduction purposes only. Everything discussed here carries real medical risks. I am not a doctor. Do your own research and consult a professional before touching any of this.
Part 1 — Growth Plates: The Foundation
Before you understand any protocol you need to understand what we are actually working with.
Growth plates (epiphyseal plates) are made of hyaline cartilage and sit between the epiphysis and metaphysis of your long bones. They are divided into three functional zones:
Resting Zone — sits at the top near the end of the bone. Cells here are mostly dormant and act as a reserve supply of chondrocytes, slowly feeding the zones below when needed.
Proliferative Zone — the active factory. Chondrocytes divide rapidly and stack into neat columns. Every division adds a small increment of bone length. This is where the majority of height gain actually happens.
Hypertrophic Zone — cells stop dividing and enlarge significantly. They mineralize the surrounding cartilage matrix and then undergo programmed death, with the hardened cartilage replaced by real bone. Last step before permanent ossification.
When all three zones stop functioning and fully ossify — growth is permanently over.
Key things most people get wrong:
Bone age is not the same as chronological age. A 16 year old with a bone age of 18 has almost no runway left. A 16 year old with a bone age of 13 has potentially years ahead of him. Getting a bone age X-ray is step one before any protocol, period.
Estrogen closes plates, not testosterone directly. Testosterone must convert to estrogen via aromatase to trigger epiphyseal fusion. Men with aromatase deficiency keep growing into their 30s. This single fact is the entire biological rationale for aromatase inhibitors in height protocols.
CXXC5 drives growth plate senescence. As puberty progresses a protein called CXXC5 gradually accumulates in the growth plate. It acts as a negative regulator of Wnt/β-catenin signaling — a biological stop-growing signal that builds up over time. Mice without CXXC5 showed delayed plate senescence and measurable tibial elongation (Choi et al., 2019). Estrogen directly upregulates CXXC5 via estrogen receptor alpha, which connects the AI strategy directly to this molecular mechanism.
The last plates to fuse are typically the clavicle and vertebral ring apophyses, which is why some people keep growing into their early 20s. There is often more runway than assumed.
Part 2 — HGH: The Gas Pedal
HGH is the primary driver of longitudinal bone growth but does not act alone.
The mechanism: GH stimulates the liver to produce IGF-1, IGF-1 binds receptors at the growth plate, chondrocyte proliferation and hypertrophy follows, and longitudinal growth occurs. GH also has direct local effects at the plate itself but IGF-1 is the dominant downstream signal.
Why dose matters: Clinical protocols for idiopathic short stature use roughly 0.3–0.5 mg/kg/week (1–3 IU/day). Higher doses elevate IGF-1 further but receptor saturation creates diminishing returns. People with gigantism who chronically overproduce GH do not appear to hit a hard cap on growth velocity, suggesting that in the right hormonal environment higher doses remain meaningful.
Dosing tiers:4–6 IU/day — solid starting point, meaningful IGF-1 elevation, manageable sides6–8 IU/day — more aggressive, noticeable water retention and joint effects begin12 IU/day — high end, significant side effect risk, requires full support protocol25+ IU/day — extreme territory, meaningful organ growth and metabolic risk, but for purely height u shouldnt be under 10+ ius and if u worried about getting uncanny dont worry u would need to be on 15+ iu for 10 years to become uncanny
HGH Timing (critical and often ignored):Inject on a completely empty stomach. Wait 15–30 minutes, then consume fast acting carbs and amino acids. This maximizes the GH pulse and IGF-1 response. Injecting after food — especially carbs — blunts the effect significantly because elevated insulin at time of injection competes with GH signaling. Morning fasted injection is the most common approach.
Thyroid drain — one of the most overlooked sides:HGH accelerates the conversion of T4 (inactive thyroid hormone) to T3 (active thyroid hormone). Over time this overworks the thyroid and can slow it down, producing symptoms like fatigue, feeling cold, poor recovery, brain fog, and weight gain despite eating normally. This is why thyroid function (TSH, Free T3, Free T4) should be included in all bloodwork panels on cycle. Some users add T4 supplementation proactively as support, especially at higher GH doses.
HGH side effects to monitor:Water retention and bloating (aldosterone/sodium retention)Joint pain and carpal tunnel (fluid pressure on median nerve)Insulin resistance (GH is anti-insulin by nature)Thyroid suppression at sustained high dosesOrgan growth (gut, kidneys, heart) at very high long term dosesAcromegalic features (jaw, brow, hands, feet) — takes years at high doses but irreversible
Pros:Muscle growth and improved body composition via IGF-1Fat loss through lipolysisFaster recoveryImproved skin collagen and elasticityStronger bones via increased bone mineral densityLongitudinal growth if plates are openBetter sleep quality
Part 3 — Support Supplements: Non-Negotiable
This section is essential and most people skip it. Every compound in this thread creates metabolic stress somewhere. These supplements directly counter the most common and serious side effects.
Berberine (1000–1500 mg/day, split into 2–3 doses with meals)HGH causes insulin resistance. Berberine activates AMPK (the same pathway as metformin) and directly improves insulin sensitivity. This is the most important metabolic support compound on a GH cycle. It also improves lipid profiles, reduces LDL, and has mild anti-inflammatory effects. Take with meals to avoid GI upset. Risks: GI discomfort at high doses, mild hypoglycemia if stacked aggressively with other insulin sensitizers. Do not stack with metformin without monitoring.
Acarbose (25–50 mg with carb-containing meals)Alpha-glucosidase inhibitor. Slows the digestion and absorption of carbohydrates, which blunts post-meal blood glucose spikes that GH exaggerates. Particularly useful around your post-injection carb intake. Works at the gut level so systemic side effects are minimal, but expect significant gas and bloating when you first start — this fades over 2–3 weeks as gut bacteria adapt. Risk: GI discomfort, do not use during hypoglycemic episodes as it blocks carb absorption and will prevent glucose recovery.
T4/Thyroid Support (dosing varies — get bloodwork first)As explained above, HGH drains the thyroid over time by accelerating T4 to T3 conversion. If bloodwork shows TSH rising or Free T3/T4 falling, low dose T4 supplementation (levothyroxine, 25–50 mcg/day is a common starting point) can restore balance. Do not start thyroid hormones without baseline bloodwork — supplementing when your thyroid is functioning normally can suppress natural production. Risks: palpitations, anxiety, insomnia, hyperthyroidism at excessive doses, permanent suppression of natural thyroid function if run too aggressively long term.
TUDCA (500–1000 mg/day)Tauroursodeoxycholic acid — a bile acid that directly protects liver cells from stress and apoptosis. Essential if you are running any oral AAS (Halotestin is significantly hepatotoxic). Reduces liver enzyme elevation, protects against cholestasis. Very well tolerated. Risks: mild GI effects at high doses, otherwise considered very safe.
Citrus Bergamot (500–1500 mg/day)Crashed E2 from AIs destroys your lipid profile — HDL drops, LDL rises, cardiovascular risk climbs. Citrus bergamot is one of the most evidence-backed natural compounds for improving cholesterol. It reduces LDL, raises HDL, and reduces triglycerides. Consider it mandatory if you are running an AI. Risks: very low, mild GI upset in some people.
Cod Liver Oil / Omega-3 (2–4 g EPA+DHA daily)Reduces systemic inflammation, supports cardiovascular health, improves lipid profile synergistically with bergamot, and protects joints which GH can stress via fluid retention and cartilage effects. Get a high quality molecularly distilled product to avoid heavy metal contamination. Risks: fishy burps, mild blood thinning at very high doses, avoid mega-dosing before surgery.
Vitamin D3 + K2Both are essential for bone mineralization. If you are growing bone you need adequate D3 (2000–5000 IU/day) paired with K2 (MK-7, 100–200 mcg/day) to direct calcium into bone rather than soft tissue. Deficiency in either will blunt the skeletal gains from your protocol.
Zinc (25–50 mg/day with food)Supports testosterone production, immune function, and IGF-1 signaling. Commonly depleted during intense training and hormonal manipulation. Take with food to avoid nausea. Do not exceed 50 mg/day long term without copper supplementation as zinc depletes copper.
Part 4 — Blood Glucose Management and Insulin
Why blood glucose matters on GH:GH is inherently anti-insulin — it raises blood glucose by suppressing peripheral glucose uptake. At high doses this becomes significant and unmanaged insulin resistance leads to chronic elevated blood sugar, which causes long term metabolic damage and paradoxically blunts IGF-1 signaling efficiency.
Blood glucose monitoring protocol:Get a cheap glucometer. Check fasted morning glucose and post-meal glucose. Target fasted BG under 100 mg/dL, post-meal under 140 mg/dL at 2 hours. If numbers are creeping up, increase berberine dose and add acarbose before carb meals.
The 10–15g carbs per IU rule:After injecting GH fasted and waiting 15–30 minutes, consume 10–15 grams of fast acting carbs per IU of GH to keep blood sugar stable and avoid hypoglycemia rebound. Pair with amino acids to maximize the IGF-1 anabolic window.
Lantus Insulin (long-acting, for advanced users only):Lantus (insulin glargine) is a 24-hour basal insulin. It is used in advanced stacks because insulin and IGF-1 are synergistic — insulin drives glucose and amino acids into cells creating a highly anabolic environment that multiplies the effect of elevated IGF-1 from GH. In the context of height, this means more fuel delivered to chondrocytes at exactly the time GH is signaling them to proliferate.
Typical starting dose: 5–10 IU subcutaneous, once daily, usually at night. Titrate slowly based on fasted morning glucose. Target fasted BG of 80–90 mg/dL.
This is genuinely dangerous. Read this carefully:Insulin overdose causes hypoglycemia which can cause seizures, brain damage, and death within minutes. Always have fast acting glucose (dextrose tablets, juice, regular soda) immediately accessible before every injection. Never inject Lantus and then go to sleep without someone who knows what you are doing nearby. Never use rapid acting insulin (Humalog, Novorapid) unless you have extensive experience — the margin for error is extremely small. Symptoms of hypoglycemia: shakiness, sweating, confusion, heart racing, vision changes. Treat immediately with 15–20g fast acting glucose and recheck in 15 minutes. Do not use insulin if you are not monitoring blood glucose regularly. Do not use insulin if you are alone, especially not at night.
Risks of long term insulin use: insulin resistance, weight gain, hypoglycemic episodes, dependency, lipodystrophy at injection sites.
This is the highest risk compound in any heightmaxxing stack. The potential synergy with GH/IGF-1 is real, but it should only be considered by those who fully understand glucose management and have all safety measures in place.
Part 5 — AIs (Aromatase Inhibitors): Stopping the Clock
The most clinically validated intervention in this entire thread alongside GH.
The biology: Aromatase converts testosterone to estrogen. Estrogen upregulates CXXC5, suppresses Wnt/β-catenin, and drives growth plate senescence and fusion. Block aromatase, keep E2 low, and the senescence clock slows dramatically.
A 2016 RCT (https://pubmed.ncbi.nlm.nih.gov/27710241/) and a 2025 meta-analysis (https://pmc.ncbi.nlm.nih.gov/articles/PMC12342369/) both confirmed that combining AIs with GH produces significantly greater adult height outcomes than GH alone in pubertal boys with idiopathic short stature. This is the most evidence-backed combination in heightmaxxing.
Letrozole (2.5 mg/day) — gold standard, most potent non-steroidal reversible AI. Crushes E2 to 5–15 pg/mL range. Most clinical height studies use this dose.
Anastrozole (0.5–1 mg/day) — weaker than letrozole but has more pediatric ISS trial data. Less aggressive suppression, which some argue is safer for bone density preservation.
Fulvestrant (Faslodex) — SERD, degrades estrogen receptors entirely rather than just blocking aromatase. Nuclear option. The ICI 182,780 mouse study (https://www.nature.com/articles/pr19992810) showed it can prevent estrogen-accelerated bone maturation even when E2 is present. Used in advanced protocols stacked with an AI for dual pathway blockade.
Exemestane (Aromasin, 12.5–25 mg EOD) — steroidal suicidal AI, permanently destroys aromatase molecules. Has a steroidal backbone which can behave differently from non-steroidal AIs. Some rat data showed reduced bone length. Controversial in this context — most community consensus leans toward letrozole.
Critical risks:Bone density loss — E2 is essential for bone mineralization. Chronic suppression while growing taller means potentially weaker bones. Counteract with Vitamin D3/K2, calcium, and Abaloparatide if running aggressive suppression. Lipid dysregulation — E2 is cardioprotective. Crashed E2 worsens cholesterol profile significantly. Run citrus bergamot and omega-3 mandatory. Joint pain, mood issues, libido loss. Potential neurological effects in adolescents — E2 plays a role in brain development during puberty. This is underresearched and a genuine unknown risk. Get bloodwork every 6–8 weeks minimum.
Part 6 — FGFR Inhibitors: Removing the Brake
FGFR3 is a negative regulator of bone growth — a biological brake signal in the growth plate. Blocking it allows the GH/IGF-1 gas pedal to work without interference.
The framework: HGH provides the raw IGF-1 anabolic signal (gas). FGFR3 inhibition removes the stop-growth signal (brake removal). Together: unimpeded growth velocity.
Infigratinib — oral FGFR1-3 inhibitor. RCT data in achondroplasia kids showed +1.74–2.50 cm/year extra annualized height velocity vs placebo (https://investor.bridgebio.com/news...roportionality-in-Achondroplasia/default.aspx). First drug to show statistically significant improvement in body proportionality in ACH. The problem: hitting FGFR1 and FGFR2 causes hyperphosphatemia and additional off-target toxicity. More studied than TYRA-300 but riskier.
TYRA-300 (Dabogratinib) — selective FGFR3 only inhibitor. First-in-class. Mouse data (https://insight.jci.org/articles/view/189307) showed significant increases in femur length (+3.7–5%), tibia length (+3.75–6%), and improved skeletal proportionality even in wild-type (normal) mice — not just ACH models. This is huge because it suggests benefit even without a pathological FGFR3 mutation. Spares FGFR1/2/4 so avoids the phosphate toxicity of infigratinib. Main issues: no human height trial data yet, very difficult to verify product purity from gray market sources, expensive.
Erdafitinib — pan-FGFR1-4 inhibitor, most potent but least selective. One case study showed extreme height velocity in a child on it for cancer treatment but also caused rapid overgrowth, kyphoscoliosis, and spinal deformities (https://www.sciencedirect.com/science/article/pii/S2405844024069184). Mechanism is proven but risk profile is the worst of the group. Not recommended.
Loxo-435 — highly selective FGFR3 inhibitor from Lilly. Promising alongside TYRA-300 but even less data available.
Vosoritide — CNP analog, works downstream of FGFR3 by raising cGMP and inhibiting the MAPK/ERK pathway rather than blocking the receptor directly. FDA approved for achondroplasia. RCT (https://www.nejm.org/doi/full/10.1056/NEJMoa1813446) showed +1.57 cm/year extra growth velocity vs placebo. Safer mechanism but weaker effect than direct FGFR3 blockade and degrades very fast requiring careful storage and daily injection. Expensive.
Honest reality check: Most FGFR compounds on the gray market are unverifiable. There are essentially no reputable lab tests confirming that what is sold as TYRA-300 or infigratinib actually contains what is claimed. For most people optimizing GH + letrozole will outperform spending money on potentially bunk FGFR compounds. TYRA-300 is worth pursuing only if you can verify pharmaceutical grade product.
Part 7 — AAS: The Double-Edged Sword
Complicated territory. AAS can both help and hurt height depending on what you use and when.
The problem with most AAS: When any androgen enters the bloodstream it reaches growth plate chondrocytes and binds directly to androgen receptors. These receptors accelerate terminal differentiation — telling chondrocytes to stop dividing and mature into bone faster. This happens regardless of dose. There is no low enough dose that completely avoids this effect. Aromatizable androgens compound this by also converting to estrogen, advancing bone age rapidly.
Halotestin (Fluoxymesterone) @ 2.5 mg/day — the most defensible option:Non-aromatizing. Cannot convert to estrogen. Provides direct AR stimulus at the growth plate, upregulating local IGF-1 receptor expression and making chondrocytes hypersensitive to the GH signal. Provides a pubertal growth stimulus without triggering the estrogen-mediated fusion pathway. The 1993 Moore study (https://pubmed.ncbi.nlm.nih.gov/8464656/) showed low-dose Halotestin in boys with growth delays resulted in final height +6.1 cm above predicted genetic baseline, with bone age advancing less than growth velocity. Keep cycles short — Halotestin is significantly hepatotoxic. Run TUDCA mandatory. Do not exceed 2.5 mg/day for height purposes.
Anavar (Oxandrolone) @ 2.5–5 mg/day:Mildest of the three. Has some pediatric ISS data. Low aromatization rate and reduces aromatizable substrate via negative feedback on HPTA. One study (https://www.jpeds.com/article/S0022-3476(71)80204-4/fulltext) showed increased height velocity but also accelerated skeletal age — some children in the trial lost 1.5–7.5 cm of predicted adult height. The velocity increase may not translate to better final height. More evidence than Halotestin but less favorable risk/reward for pure height purposes.
Winstrol (Stanozolol):Animal data (https://pubmed.ncbi.nlm.nih.gov/21823523/) shows direct effects on growth plate chondrocytes via estrogen receptor pathways. Less data than the other two. Not a first choice for height.
Masteron, Primobolan: Non-aromatizing, mild. Less data for height specifically but lower risk profile than Halotestin. May be useful for androgenic stimulus with lower hepatotoxicity.
Bottom line: If you use any AAS on a height protocol use the lowest effective dose of a non-aromatizing compound and stack mandatorily with an AI. Never use testosterone or aromatizable androgens without an AI. Monitor bone age every 4–6 months. The younger you are the more conservative you need to be.
Part 8 — Advanced Compounds
KY19382 — Wnt/β-catenin Reactivation:Small molecule CXXC5-DVL inhibitor. By disrupting the CXXC5-Dvl interaction it stabilizes nuclear β-catenin and reactivates Wnt signaling in the growth plate — directly reversing the senescence mechanism. Mouse data (https://pmc.ncbi.nlm.nih.gov/articles/PMC6458850/): 0.1 mg/kg daily for 10 weeks produced statistically significant tibial elongation (p<0.0005), increased proliferating chondrocytes, expanded proliferative and hypertrophic zones. Also promotes facial bone remodeling via periosteal apposition. Administration: subcutaneous injection preferred over transdermal. Caveats: all data is preclinical (mouse/cell line), no human height trials, Wnt pathway activation warrants cancer monitoring (though in cancer cell lines KY19382 showed anti-tumor effects via CDK1 suppression suggesting context-dependent behavior).
FOXO4-DRI — Senolytic Clearance:Synthetic peptide that selectively eliminates senescent cells by disrupting the FOXO4-p53 protective interaction, triggering apoptosis specifically in senescent chondrocytes. Rationale: senescent chondrocytes secrete SASP inflammatory factors (IL-6, MMPs) that create a toxic microenvironment suppressing nearby healthy chondrocytes and depleting the resting zone stem cell pool. Clearing them reduces this inflammatory burden and allows the remaining healthy chondrocytes to proliferate more freely. Highly theoretical for height in humans. No human data. Interesting mechanism but not something most people should approach casually.
SAG21k / Purmorphamine — Hedgehog Pathway:Small molecules that directly activate Smoothened (SMO) in the Hedgehog signaling pathway, bypassing normal Patched inhibition and activating Gli transcription factors. Effect: more epiphyseal stem cells multiply, chondrocyte columns thicken, growth plates become more active. Mouse data (https://pmc.ncbi.nlm.nih.gov/articles/PMC10506518/) showed strong enhancement of chondrogenesis. Major concern: Hedgehog pathway overactivation is strongly linked to cancer development. This is not a minor theoretical risk — sustained Hh pathway activation is a known driver of multiple cancer types. Only worth considering in very strategic short term windows if at all.
SOCS2 Inhibition:SOCS2 is a negative feedback regulator of GH signaling. It binds the phosphorylated GH receptor, promotes its degradation, and dampens STAT5 activation and IGF-1 production. Inhibiting SOCS2 removes this brake on GH signaling itself — essentially amplifying exogenous GH. Mice without SOCS2 grew 30–40% larger than wild-type with increased long-bone length (https://www.nature.com/articles/35016611). A human SOCS2 mutation was linked to gigantism. Risks: chronic GH/IGF-1 hypersignaling causes insulin resistance, potential organ enlargement, and IGF-1 is mitogenic meaning cancer risk with chronic elevation.
SCO-240 — Endogenous GH Amplification:Oral SSTR5 antagonist. Somatostatin normally inhibits GH release by binding SSTR5 on pituitary somatotrophs. SCO-240 blocks this, allowing the pituitary to release more GH in a physiological pulsatile pattern without affecting other pituitary hormones. Phase 1 data (https://pubmed.ncbi.nlm.nih.gov/38549435/) showed robust dose-dependent GH secretion comparable to therapeutic rhGH levels. Advantage over injected GH: mimics natural pulsatile pattern more closely. Disadvantages: only Phase 1 adult data, no height efficacy data in children yet, still carries standard GH excess risks.
Abaloparatide / Teriparatide — PTHrP Analogs:Both bind PTH1R, mimicking the natural PTHrP signal that keeps chondrocytes in the proliferative state and delays hypertrophic transition. Intermittent daily dosing expands proliferative and hypertrophic zones, increases chondrocyte columns, and prolongs the active growth window before senescence. Abaloparatide more closely mimics PTHrP's natural growth plate role, potentially providing a cleaner anabolic effect with less calcium/resorption side effects than teriparatide. Abalo also counteracts the bone density loss caused by aggressive AI use — making it arguably mandatory at the advanced level. Main risk: rat studies at high doses showed osteosarcoma signal. Clinical doses appear significantly below the threshold where this was observed but it is a real consideration for long term use.
Epitalon (Telomerase Activator):Aims to reduce the biological age of chondrocytes by activating telomerase and slowing cellular senescence. Highly speculative for height. The concept of keeping chondrocytes biologically younger for longer is mechanistically sound but human height data does not exist. Low risk profile. Subcutaneous injection.
Forskolin (20–50 mg/day)directly activates adenylyl cyclase, increases intracellular cAMP, and amplifies the mitogenic effects of IGF-1 and GH within chondrocytes. Makes the growth signal hit harder at the cellular level. Relatively accessible, low risk compared to everything else here. GI upset possible at higher doses.
Tamoxifen:SERM — selectively blocks estrogen receptors in some tissues. One study (https://pubmed.ncbi.nlm.nih.gov/16322179/) in 7 short pubertal boys showed tamoxifen significantly slowed skeletal maturation and increased predicted adult height by around 4 inches with no negative effects on puberty progression. However a rat study (https://pubmed.ncbi.nlm.nih.gov/18348701/) showed persistent shorter tibia, reduced cortical bone size, increased chondrocyte apoptosis, and lowered IGF-1. The evidence is too limited and contradictory to recommend over a proper AI. Stick to letrozole or anastrozole.
Part 9 — The Full Protocol Framework
Core (most evidence-backed):HGH: 6–12 IU/day, injected fasted, wait 15–30 min, then fast carbs plus aminosLetrozole: 2.5 mg/dayBerberine: 1000–1500 mg/day with mealsAcarbose: 25–50 mg with carb mealsTUDCA: 500–1000 mg/dayCitrus Bergamot: 500–1500 mg/dayOmega-3: 2–4 g EPA+DHA dailyVitamin D3/K2: 3000–5000 IU D3 plus 100–200 mcg K2 dailyThyroid monitoring (TSH, Free T3, Free T4) — T4 support if neededBlood glucose monitoring — target fasted under 100 mg/dL
Intermediate additions:TYRA-300 (selective FGFR3 inhibitor) — if verifiably pharmaceutical gradeHalotestin 2.5 mg/day — short cycles only, TUDCA mandatoryAbaloparatide — PTHrP signaling, bone density protection from AI useLantus insulin (5–10 IU baseline) — only with full glucose monitoring protocol and safety measures in placeForskolin 20–50 mg/day
Advanced (frontier territory, mostly preclinical data):KY19382 — Wnt/β-catenin reactivation, subcutaneousFOXO4-DRI — senolytic clearance of growth plateSCO-240 — endogenous GH amplificationSOCS2 inhibition — GH signaling amplification
For post-pubescent / closing plates:The aggressive multi-compound stack has diminishing returns once plates are fused. Focus shifts to: maximizing remaining open plates (clavicle, vertebral apophyses), spinal decompression, posture correction. KY19382 and abaloparatide may still be relevant for residual growth centers. Bone density protection becomes more important than growth velocity at this stage.
Part 10 — Bloodwork: Non-Negotiable
Get baseline before starting anything. Repeat at 6 weeks on cycle, then every 2–3 months.
What to check:IGF-1 — confirms GH is working and not bunk, tracks your responseEstradiol (E2) — confirms AI is working, avoid crashing below 5 pg/mLTotal + Free Testosterone — track suppression from AAS if applicableLH / FSH — track HPTA suppressionTSH, Free T3, Free T4 — thyroid health, essential on GHFasting glucose + HbA1c — metabolic health, GH insulin resistanceLipid panel (LDL, HDL, triglycerides) — AI will worsen this, monitorLiver enzymes (ALT, AST) — essential if running any oral AASBone age X-ray — every 4–6 months to track skeletal maturation vs growth velocity
If you are not monitoring bloodwork you are flying blind and have no idea if what you are doing is helping or destroying you.
Part 11 — Risks: Read This Before You Do Anything
This needs to be said clearly and seriously.
You are intervening in the most complex hormonal system in the human body during what may be its most sensitive developmental window. Most of these compounds have no safety data in healthy adolescents. The clinical data that exists is in children with diagnosed growth disorders under close medical supervision with regular monitoring.
Specific serious risks permanent endocrine disruption from AAS/AI misuse — HPTA suppression, infertility, hormonal dysregulation that does not fully recoverBone density loss from chronic E2 suppression — growing taller with structurally weaker bonesOrgan hypertrophy from excessive long-term GH — heart, kidneys, intestinesScoliosis and spinal deformity from aggressive FGFR inhibitionHepatotoxicity from oral AAS — Halotestin is seriously liver toxic, do not run it long termHypoglycemia from insulin — can cause seizures, brain damage, deathCancer risk from Wnt pathway agonists and Hedgehog activators — theoretical but real pathwaysUsing unverified gray market compounds that may be entirely bunk or contaminated with unknown substancesPsychological dependence on external hormonal manipulationBrain development effects from E2 suppression in adolescence — genuinely underresearched
The honest reality: There are no guarantees. You can take everything on this list perfectly and get zero height, or get sides with no growth. How your body responds is heavily genetic. No verified hyper-responder exists in the community. Someone who follows this thread may get 6 cm of extra height. Someone else might get organ issues and nothing else.
If you are a minor considering any of this: at minimum do this with regular bloodwork and ideally with a doctor who understands the compounds involved.
Sources
AI + GH Clinical:https://pubmed.ncbi.nlm.nih.gov/277...om/doi/abs/10.1111/j.1651-2227.1963.tb03805.x
Estrogen and Fusion:https://www.nature.com/articles/pr19992810
CXXC5 / KY19382 / Wnt:https://pmc.ncbi.nlm.nih.gov/articl...tionhttps://pubmed.ncbi.nlm.nih.gov/30971423/
FGFR Inhibitors:https://investor.bridgebio.com/news...://pmc.ncbi.nlm.nih.gov/articles/PMC12668719/
PTHrP / Abaloparatide / Vosoritide:https://www.nejm.org/doi/full/10.1056/NEJMoa1813446
AAS:https://www.jpeds.com/article/S0022...3523/https://pubmed.ncbi.nlm.nih.gov/8464656/
Tamoxifen:https://pubmed.ncbi.nlm.nih.gov/16322179/https://pubmed.ncbi.nlm.nih.gov/18348701/
SOCS2:https://www.nature.com/articles/350...blication/linked-with-missense-mutation-SOCS2
SAG21k:https://pmc.ncbi.nlm.nih.gov/articles/PMC10506518/
SCO-240:https://pubmed.ncbi.nlm.nih.gov/38549435/
This thread is for educational purposes only. Nothing here is medical advice. Everything discussed carries real risks. Do your research, get bloodwork, and if possible work with a doctor who understands what you are doing.
TAGS:
@Zagro,@Menas,@Chad ,@Typhon , @Orka rate the thread
@FutureSlayer can u take away my 90% warning high effort post
monthly costs of 12iu 5 days on and 2 days of is around 260 dollars if u find the right source thats pretty cheap if u have a job
big shout out to Choh Hao li for HghView attachment 4996545
???read every atom
i did make some mistakes troughout the thread but i cant edit it and fixx it now so too late i can answer quesitons if u rep every single post of mineread every atom
dont need to ask any questions besides how the fuck do you expect ppl to source TYRA-300
indianmart or lmpeptides overpriced but it worksdont need to ask any questions besides how the fuck do you expect ppl to source TYRA-300
if u want a link rep every post of me in this thread and i will senddont need to ask any questions besides how the fuck do you expect ppl to source TYRA-300
fine nigger fine
sent the source
u can read it now
how old are u? ur spinal plates may still be open and if u blast 30ius u might grow a lil
I turn 16 in a couple weeks and I haven’t grown in two years so I’m not expecting much.
ideas on erda, abalo, gh, forskolin, sacubitril for less cnp breakdown, cilostazol for the cAMP breakdown decrease, mn714, (post has good info to someone whos starting out, but it sound very gpt-like which might be why its not getting love)
Heightmaxing Guide 101
Thread song:
ive been studying this topic since i learned about it and i have ordered my stack and everything is ready enough about that though tho. In this thread I will go through a couple of things like growth plates, HGH, AIs, AAS, FGFR inhibitors, and more. Some of the topics I will talk about are pretty new knowledge so don't bash on me if I am wrong cuz I'm trying my best
This thread is for educational and harm reduction purposes only. Everything discussed here carries real medical risks. I am not a doctor. Do your own research and consult a professional before touching any of this.
Part 1 — Growth Plates: The Foundation
Before you understand any protocol you need to understand what we are actually working with.
Growth plates (epiphyseal plates) are made of hyaline cartilage and sit between the epiphysis and metaphysis of your long bones. They are divided into three functional zones:
Resting Zone — sits at the top near the end of the bone. Cells here are mostly dormant and act as a reserve supply of chondrocytes, slowly feeding the zones below when needed.
Proliferative Zone — the active factory. Chondrocytes divide rapidly and stack into neat columns. Every division adds a small increment of bone length. This is where the majority of height gain actually happens.
Hypertrophic Zone — cells stop dividing and enlarge significantly. They mineralize the surrounding cartilage matrix and then undergo programmed death, with the hardened cartilage replaced by real bone. Last step before permanent ossification.
When all three zones stop functioning and fully ossify — growth is permanently over.
Key things most people get wrong:
Bone age is not the same as chronological age. A 16 year old with a bone age of 18 has almost no runway left. A 16 year old with a bone age of 13 has potentially years ahead of him. Getting a bone age X-ray is step one before any protocol, period.
Estrogen closes plates, not testosterone directly. Testosterone must convert to estrogen via aromatase to trigger epiphyseal fusion. Men with aromatase deficiency keep growing into their 30s. This single fact is the entire biological rationale for aromatase inhibitors in height protocols.
CXXC5 drives growth plate senescence. As puberty progresses a protein called CXXC5 gradually accumulates in the growth plate. It acts as a negative regulator of Wnt/β-catenin signaling — a biological stop-growing signal that builds up over time. Mice without CXXC5 showed delayed plate senescence and measurable tibial elongation (Choi et al., 2019). Estrogen directly upregulates CXXC5 via estrogen receptor alpha, which connects the AI strategy directly to this molecular mechanism.
The last plates to fuse are typically the clavicle and vertebral ring apophyses, which is why some people keep growing into their early 20s. There is often more runway than assumed.
Part 2 — HGH: The Gas Pedal
HGH is the primary driver of longitudinal bone growth but does not act alone.
The mechanism: GH stimulates the liver to produce IGF-1, IGF-1 binds receptors at the growth plate, chondrocyte proliferation and hypertrophy follows, and longitudinal growth occurs. GH also has direct local effects at the plate itself but IGF-1 is the dominant downstream signal.
Why dose matters: Clinical protocols for idiopathic short stature use roughly 0.3–0.5 mg/kg/week (1–3 IU/day). Higher doses elevate IGF-1 further but receptor saturation creates diminishing returns. People with gigantism who chronically overproduce GH do not appear to hit a hard cap on growth velocity, suggesting that in the right hormonal environment higher doses remain meaningful.
Dosing tiers:4–6 IU/day — solid starting point, meaningful IGF-1 elevation, manageable sides6–8 IU/day — more aggressive, noticeable water retention and joint effects begin12 IU/day — high end, significant side effect risk, requires full support protocol25+ IU/day — extreme territory, meaningful organ growth and metabolic risk, but for purely height u shouldnt be under 10+ ius and if u worried about getting uncanny dont worry u would need to be on 15+ iu for 10 years to become uncanny
HGH Timing (critical and often ignored):Inject on a completely empty stomach. Wait 15–30 minutes, then consume fast acting carbs and amino acids. This maximizes the GH pulse and IGF-1 response. Injecting after food — especially carbs — blunts the effect significantly because elevated insulin at time of injection competes with GH signaling. Morning fasted injection is the most common approach.
Thyroid drain — one of the most overlooked sides:HGH accelerates the conversion of T4 (inactive thyroid hormone) to T3 (active thyroid hormone). Over time this overworks the thyroid and can slow it down, producing symptoms like fatigue, feeling cold, poor recovery, brain fog, and weight gain despite eating normally. This is why thyroid function (TSH, Free T3, Free T4) should be included in all bloodwork panels on cycle. Some users add T4 supplementation proactively as support, especially at higher GH doses.
HGH side effects to monitor:Water retention and bloating (aldosterone/sodium retention)Joint pain and carpal tunnel (fluid pressure on median nerve)Insulin resistance (GH is anti-insulin by nature)Thyroid suppression at sustained high dosesOrgan growth (gut, kidneys, heart) at very high long term dosesAcromegalic features (jaw, brow, hands, feet) — takes years at high doses but irreversible
Pros:Muscle growth and improved body composition via IGF-1Fat loss through lipolysisFaster recoveryImproved skin collagen and elasticityStronger bones via increased bone mineral densityLongitudinal growth if plates are openBetter sleep quality
Part 3 — Support Supplements: Non-Negotiable
This section is essential and most people skip it. Every compound in this thread creates metabolic stress somewhere. These supplements directly counter the most common and serious side effects.
Berberine (1000–1500 mg/day, split into 2–3 doses with meals)HGH causes insulin resistance. Berberine activates AMPK (the same pathway as metformin) and directly improves insulin sensitivity. This is the most important metabolic support compound on a GH cycle. It also improves lipid profiles, reduces LDL, and has mild anti-inflammatory effects. Take with meals to avoid GI upset. Risks: GI discomfort at high doses, mild hypoglycemia if stacked aggressively with other insulin sensitizers. Do not stack with metformin without monitoring.
Acarbose (25–50 mg with carb-containing meals)Alpha-glucosidase inhibitor. Slows the digestion and absorption of carbohydrates, which blunts post-meal blood glucose spikes that GH exaggerates. Particularly useful around your post-injection carb intake. Works at the gut level so systemic side effects are minimal, but expect significant gas and bloating when you first start — this fades over 2–3 weeks as gut bacteria adapt. Risk: GI discomfort, do not use during hypoglycemic episodes as it blocks carb absorption and will prevent glucose recovery.
T4/Thyroid Support (dosing varies — get bloodwork first)As explained above, HGH drains the thyroid over time by accelerating T4 to T3 conversion. If bloodwork shows TSH rising or Free T3/T4 falling, low dose T4 supplementation (levothyroxine, 25–50 mcg/day is a common starting point) can restore balance. Do not start thyroid hormones without baseline bloodwork — supplementing when your thyroid is functioning normally can suppress natural production. Risks: palpitations, anxiety, insomnia, hyperthyroidism at excessive doses, permanent suppression of natural thyroid function if run too aggressively long term.
TUDCA (500–1000 mg/day)Tauroursodeoxycholic acid — a bile acid that directly protects liver cells from stress and apoptosis. Essential if you are running any oral AAS (Halotestin is significantly hepatotoxic). Reduces liver enzyme elevation, protects against cholestasis. Very well tolerated. Risks: mild GI effects at high doses, otherwise considered very safe.
Citrus Bergamot (500–1500 mg/day)Crashed E2 from AIs destroys your lipid profile — HDL drops, LDL rises, cardiovascular risk climbs. Citrus bergamot is one of the most evidence-backed natural compounds for improving cholesterol. It reduces LDL, raises HDL, and reduces triglycerides. Consider it mandatory if you are running an AI. Risks: very low, mild GI upset in some people.
Cod Liver Oil / Omega-3 (2–4 g EPA+DHA daily)Reduces systemic inflammation, supports cardiovascular health, improves lipid profile synergistically with bergamot, and protects joints which GH can stress via fluid retention and cartilage effects. Get a high quality molecularly distilled product to avoid heavy metal contamination. Risks: fishy burps, mild blood thinning at very high doses, avoid mega-dosing before surgery.
Vitamin D3 + K2Both are essential for bone mineralization. If you are growing bone you need adequate D3 (2000–5000 IU/day) paired with K2 (MK-7, 100–200 mcg/day) to direct calcium into bone rather than soft tissue. Deficiency in either will blunt the skeletal gains from your protocol.
Zinc (25–50 mg/day with food)Supports testosterone production, immune function, and IGF-1 signaling. Commonly depleted during intense training and hormonal manipulation. Take with food to avoid nausea. Do not exceed 50 mg/day long term without copper supplementation as zinc depletes copper.
Part 4 — Blood Glucose Management and Insulin
Why blood glucose matters on GH:GH is inherently anti-insulin — it raises blood glucose by suppressing peripheral glucose uptake. At high doses this becomes significant and unmanaged insulin resistance leads to chronic elevated blood sugar, which causes long term metabolic damage and paradoxically blunts IGF-1 signaling efficiency.
Blood glucose monitoring protocol:Get a cheap glucometer. Check fasted morning glucose and post-meal glucose. Target fasted BG under 100 mg/dL, post-meal under 140 mg/dL at 2 hours. If numbers are creeping up, increase berberine dose and add acarbose before carb meals.
The 10–15g carbs per IU rule:After injecting GH fasted and waiting 15–30 minutes, consume 10–15 grams of fast acting carbs per IU of GH to keep blood sugar stable and avoid hypoglycemia rebound. Pair with amino acids to maximize the IGF-1 anabolic window.
Lantus Insulin (long-acting, for advanced users only):Lantus (insulin glargine) is a 24-hour basal insulin. It is used in advanced stacks because insulin and IGF-1 are synergistic — insulin drives glucose and amino acids into cells creating a highly anabolic environment that multiplies the effect of elevated IGF-1 from GH. In the context of height, this means more fuel delivered to chondrocytes at exactly the time GH is signaling them to proliferate.
Typical starting dose: 5–10 IU subcutaneous, once daily, usually at night. Titrate slowly based on fasted morning glucose. Target fasted BG of 80–90 mg/dL.
This is genuinely dangerous. Read this carefully:Insulin overdose causes hypoglycemia which can cause seizures, brain damage, and death within minutes. Always have fast acting glucose (dextrose tablets, juice, regular soda) immediately accessible before every injection. Never inject Lantus and then go to sleep without someone who knows what you are doing nearby. Never use rapid acting insulin (Humalog, Novorapid) unless you have extensive experience — the margin for error is extremely small. Symptoms of hypoglycemia: shakiness, sweating, confusion, heart racing, vision changes. Treat immediately with 15–20g fast acting glucose and recheck in 15 minutes. Do not use insulin if you are not monitoring blood glucose regularly. Do not use insulin if you are alone, especially not at night.
Risks of long term insulin use: insulin resistance, weight gain, hypoglycemic episodes, dependency, lipodystrophy at injection sites.
This is the highest risk compound in any heightmaxxing stack. The potential synergy with GH/IGF-1 is real, but it should only be considered by those who fully understand glucose management and have all safety measures in place.
Part 5 — AIs (Aromatase Inhibitors): Stopping the Clock
The most clinically validated intervention in this entire thread alongside GH.
The biology: Aromatase converts testosterone to estrogen. Estrogen upregulates CXXC5, suppresses Wnt/β-catenin, and drives growth plate senescence and fusion. Block aromatase, keep E2 low, and the senescence clock slows dramatically.
A 2016 RCT (https://pubmed.ncbi.nlm.nih.gov/27710241/) and a 2025 meta-analysis (https://pmc.ncbi.nlm.nih.gov/articles/PMC12342369/) both confirmed that combining AIs with GH produces significantly greater adult height outcomes than GH alone in pubertal boys with idiopathic short stature. This is the most evidence-backed combination in heightmaxxing.
Letrozole (2.5 mg/day) — gold standard, most potent non-steroidal reversible AI. Crushes E2 to 5–15 pg/mL range. Most clinical height studies use this dose.
Anastrozole (0.5–1 mg/day) — weaker than letrozole but has more pediatric ISS trial data. Less aggressive suppression, which some argue is safer for bone density preservation.
Fulvestrant (Faslodex) — SERD, degrades estrogen receptors entirely rather than just blocking aromatase. Nuclear option. The ICI 182,780 mouse study (https://www.nature.com/articles/pr19992810) showed it can prevent estrogen-accelerated bone maturation even when E2 is present. Used in advanced protocols stacked with an AI for dual pathway blockade.
Exemestane (Aromasin, 12.5–25 mg EOD) — steroidal suicidal AI, permanently destroys aromatase molecules. Has a steroidal backbone which can behave differently from non-steroidal AIs. Some rat data showed reduced bone length. Controversial in this context — most community consensus leans toward letrozole.
Critical risks:Bone density loss — E2 is essential for bone mineralization. Chronic suppression while growing taller means potentially weaker bones. Counteract with Vitamin D3/K2, calcium, and Abaloparatide if running aggressive suppression. Lipid dysregulation — E2 is cardioprotective. Crashed E2 worsens cholesterol profile significantly. Run citrus bergamot and omega-3 mandatory. Joint pain, mood issues, libido loss. Potential neurological effects in adolescents — E2 plays a role in brain development during puberty. This is underresearched and a genuine unknown risk. Get bloodwork every 6–8 weeks minimum.
Part 6 — FGFR Inhibitors: Removing the Brake
FGFR3 is a negative regulator of bone growth — a biological brake signal in the growth plate. Blocking it allows the GH/IGF-1 gas pedal to work without interference.
The framework: HGH provides the raw IGF-1 anabolic signal (gas). FGFR3 inhibition removes the stop-growth signal (brake removal). Together: unimpeded growth velocity.
Infigratinib — oral FGFR1-3 inhibitor. RCT data in achondroplasia kids showed +1.74–2.50 cm/year extra annualized height velocity vs placebo (https://investor.bridgebio.com/news...roportionality-in-Achondroplasia/default.aspx). First drug to show statistically significant improvement in body proportionality in ACH. The problem: hitting FGFR1 and FGFR2 causes hyperphosphatemia and additional off-target toxicity. More studied than TYRA-300 but riskier.
TYRA-300 (Dabogratinib) — selective FGFR3 only inhibitor. First-in-class. Mouse data (https://insight.jci.org/articles/view/189307) showed significant increases in femur length (+3.7–5%), tibia length (+3.75–6%), and improved skeletal proportionality even in wild-type (normal) mice — not just ACH models. This is huge because it suggests benefit even without a pathological FGFR3 mutation. Spares FGFR1/2/4 so avoids the phosphate toxicity of infigratinib. Main issues: no human height trial data yet, very difficult to verify product purity from gray market sources, expensive.
Erdafitinib — pan-FGFR1-4 inhibitor, most potent but least selective. One case study showed extreme height velocity in a child on it for cancer treatment but also caused rapid overgrowth, kyphoscoliosis, and spinal deformities (https://www.sciencedirect.com/science/article/pii/S2405844024069184). Mechanism is proven but risk profile is the worst of the group. Not recommended.
Loxo-435 — highly selective FGFR3 inhibitor from Lilly. Promising alongside TYRA-300 but even less data available.
Vosoritide — CNP analog, works downstream of FGFR3 by raising cGMP and inhibiting the MAPK/ERK pathway rather than blocking the receptor directly. FDA approved for achondroplasia. RCT (https://www.nejm.org/doi/full/10.1056/NEJMoa1813446) showed +1.57 cm/year extra growth velocity vs placebo. Safer mechanism but weaker effect than direct FGFR3 blockade and degrades very fast requiring careful storage and daily injection. Expensive.
Honest reality check: Most FGFR compounds on the gray market are unverifiable. There are essentially no reputable lab tests confirming that what is sold as TYRA-300 or infigratinib actually contains what is claimed. For most people optimizing GH + letrozole will outperform spending money on potentially bunk FGFR compounds. TYRA-300 is worth pursuing only if you can verify pharmaceutical grade product.
Part 7 — AAS: The Double-Edged Sword
Complicated territory. AAS can both help and hurt height depending on what you use and when.
The problem with most AAS: When any androgen enters the bloodstream it reaches growth plate chondrocytes and binds directly to androgen receptors. These receptors accelerate terminal differentiation — telling chondrocytes to stop dividing and mature into bone faster. This happens regardless of dose. There is no low enough dose that completely avoids this effect. Aromatizable androgens compound this by also converting to estrogen, advancing bone age rapidly.
Halotestin (Fluoxymesterone) @ 2.5 mg/day — the most defensible option:Non-aromatizing. Cannot convert to estrogen. Provides direct AR stimulus at the growth plate, upregulating local IGF-1 receptor expression and making chondrocytes hypersensitive to the GH signal. Provides a pubertal growth stimulus without triggering the estrogen-mediated fusion pathway. The 1993 Moore study (https://pubmed.ncbi.nlm.nih.gov/8464656/) showed low-dose Halotestin in boys with growth delays resulted in final height +6.1 cm above predicted genetic baseline, with bone age advancing less than growth velocity. Keep cycles short — Halotestin is significantly hepatotoxic. Run TUDCA mandatory. Do not exceed 2.5 mg/day for height purposes.
Anavar (Oxandrolone) @ 2.5–5 mg/day:Mildest of the three. Has some pediatric ISS data. Low aromatization rate and reduces aromatizable substrate via negative feedback on HPTA. One study (https://www.jpeds.com/article/S0022-3476(71)80204-4/fulltext) showed increased height velocity but also accelerated skeletal age — some children in the trial lost 1.5–7.5 cm of predicted adult height. The velocity increase may not translate to better final height. More evidence than Halotestin but less favorable risk/reward for pure height purposes.
Winstrol (Stanozolol):Animal data (https://pubmed.ncbi.nlm.nih.gov/21823523/) shows direct effects on growth plate chondrocytes via estrogen receptor pathways. Less data than the other two. Not a first choice for height.
Masteron, Primobolan: Non-aromatizing, mild. Less data for height specifically but lower risk profile than Halotestin. May be useful for androgenic stimulus with lower hepatotoxicity.
Bottom line: If you use any AAS on a height protocol use the lowest effective dose of a non-aromatizing compound and stack mandatorily with an AI. Never use testosterone or aromatizable androgens without an AI. Monitor bone age every 4–6 months. The younger you are the more conservative you need to be.
Part 8 — Advanced Compounds
KY19382 — Wnt/β-catenin Reactivation:Small molecule CXXC5-DVL inhibitor. By disrupting the CXXC5-Dvl interaction it stabilizes nuclear β-catenin and reactivates Wnt signaling in the growth plate — directly reversing the senescence mechanism. Mouse data (https://pmc.ncbi.nlm.nih.gov/articles/PMC6458850/): 0.1 mg/kg daily for 10 weeks produced statistically significant tibial elongation (p<0.0005), increased proliferating chondrocytes, expanded proliferative and hypertrophic zones. Also promotes facial bone remodeling via periosteal apposition. Administration: subcutaneous injection preferred over transdermal. Caveats: all data is preclinical (mouse/cell line), no human height trials, Wnt pathway activation warrants cancer monitoring (though in cancer cell lines KY19382 showed anti-tumor effects via CDK1 suppression suggesting context-dependent behavior).
FOXO4-DRI — Senolytic Clearance:Synthetic peptide that selectively eliminates senescent cells by disrupting the FOXO4-p53 protective interaction, triggering apoptosis specifically in senescent chondrocytes. Rationale: senescent chondrocytes secrete SASP inflammatory factors (IL-6, MMPs) that create a toxic microenvironment suppressing nearby healthy chondrocytes and depleting the resting zone stem cell pool. Clearing them reduces this inflammatory burden and allows the remaining healthy chondrocytes to proliferate more freely. Highly theoretical for height in humans. No human data. Interesting mechanism but not something most people should approach casually.
SAG21k / Purmorphamine — Hedgehog Pathway:Small molecules that directly activate Smoothened (SMO) in the Hedgehog signaling pathway, bypassing normal Patched inhibition and activating Gli transcription factors. Effect: more epiphyseal stem cells multiply, chondrocyte columns thicken, growth plates become more active. Mouse data (https://pmc.ncbi.nlm.nih.gov/articles/PMC10506518/) showed strong enhancement of chondrogenesis. Major concern: Hedgehog pathway overactivation is strongly linked to cancer development. This is not a minor theoretical risk — sustained Hh pathway activation is a known driver of multiple cancer types. Only worth considering in very strategic short term windows if at all.
SOCS2 Inhibition:SOCS2 is a negative feedback regulator of GH signaling. It binds the phosphorylated GH receptor, promotes its degradation, and dampens STAT5 activation and IGF-1 production. Inhibiting SOCS2 removes this brake on GH signaling itself — essentially amplifying exogenous GH. Mice without SOCS2 grew 30–40% larger than wild-type with increased long-bone length (https://www.nature.com/articles/35016611). A human SOCS2 mutation was linked to gigantism. Risks: chronic GH/IGF-1 hypersignaling causes insulin resistance, potential organ enlargement, and IGF-1 is mitogenic meaning cancer risk with chronic elevation.
SCO-240 — Endogenous GH Amplification:Oral SSTR5 antagonist. Somatostatin normally inhibits GH release by binding SSTR5 on pituitary somatotrophs. SCO-240 blocks this, allowing the pituitary to release more GH in a physiological pulsatile pattern without affecting other pituitary hormones. Phase 1 data (https://pubmed.ncbi.nlm.nih.gov/38549435/) showed robust dose-dependent GH secretion comparable to therapeutic rhGH levels. Advantage over injected GH: mimics natural pulsatile pattern more closely. Disadvantages: only Phase 1 adult data, no height efficacy data in children yet, still carries standard GH excess risks.
Abaloparatide / Teriparatide — PTHrP Analogs:Both bind PTH1R, mimicking the natural PTHrP signal that keeps chondrocytes in the proliferative state and delays hypertrophic transition. Intermittent daily dosing expands proliferative and hypertrophic zones, increases chondrocyte columns, and prolongs the active growth window before senescence. Abaloparatide more closely mimics PTHrP's natural growth plate role, potentially providing a cleaner anabolic effect with less calcium/resorption side effects than teriparatide. Abalo also counteracts the bone density loss caused by aggressive AI use — making it arguably mandatory at the advanced level. Main risk: rat studies at high doses showed osteosarcoma signal. Clinical doses appear significantly below the threshold where this was observed but it is a real consideration for long term use.
Epitalon (Telomerase Activator):Aims to reduce the biological age of chondrocytes by activating telomerase and slowing cellular senescence. Highly speculative for height. The concept of keeping chondrocytes biologically younger for longer is mechanistically sound but human height data does not exist. Low risk profile. Subcutaneous injection.
Forskolin (20–50 mg/day)directly activates adenylyl cyclase, increases intracellular cAMP, and amplifies the mitogenic effects of IGF-1 and GH within chondrocytes. Makes the growth signal hit harder at the cellular level. Relatively accessible, low risk compared to everything else here. GI upset possible at higher doses.
Tamoxifen:SERM — selectively blocks estrogen receptors in some tissues. One study (https://pubmed.ncbi.nlm.nih.gov/16322179/) in 7 short pubertal boys showed tamoxifen significantly slowed skeletal maturation and increased predicted adult height by around 4 inches with no negative effects on puberty progression. However a rat study (https://pubmed.ncbi.nlm.nih.gov/18348701/) showed persistent shorter tibia, reduced cortical bone size, increased chondrocyte apoptosis, and lowered IGF-1. The evidence is too limited and contradictory to recommend over a proper AI. Stick to letrozole or anastrozole.
Part 9 — The Full Protocol Framework
Core (most evidence-backed):HGH: 6–12 IU/day, injected fasted, wait 15–30 min, then fast carbs plus aminosLetrozole: 2.5 mg/dayBerberine: 1000–1500 mg/day with mealsAcarbose: 25–50 mg with carb mealsTUDCA: 500–1000 mg/dayCitrus Bergamot: 500–1500 mg/dayOmega-3: 2–4 g EPA+DHA dailyVitamin D3/K2: 3000–5000 IU D3 plus 100–200 mcg K2 dailyThyroid monitoring (TSH, Free T3, Free T4) — T4 support if neededBlood glucose monitoring — target fasted under 100 mg/dL
Intermediate additions:TYRA-300 (selective FGFR3 inhibitor) — if verifiably pharmaceutical gradeHalotestin 2.5 mg/day — short cycles only, TUDCA mandatoryAbaloparatide — PTHrP signaling, bone density protection from AI useLantus insulin (5–10 IU baseline) — only with full glucose monitoring protocol and safety measures in placeForskolin 20–50 mg/day
Advanced (frontier territory, mostly preclinical data):KY19382 — Wnt/β-catenin reactivation, subcutaneousFOXO4-DRI — senolytic clearance of growth plateSCO-240 — endogenous GH amplificationSOCS2 inhibition — GH signaling amplification
For post-pubescent / closing plates:The aggressive multi-compound stack has diminishing returns once plates are fused. Focus shifts to: maximizing remaining open plates (clavicle, vertebral apophyses), spinal decompression, posture correction. KY19382 and abaloparatide may still be relevant for residual growth centers. Bone density protection becomes more important than growth velocity at this stage.
Part 10 — Bloodwork: Non-Negotiable
Get baseline before starting anything. Repeat at 6 weeks on cycle, then every 2–3 months.
What to check:IGF-1 — confirms GH is working and not bunk, tracks your responseEstradiol (E2) — confirms AI is working, avoid crashing below 5 pg/mLTotal + Free Testosterone — track suppression from AAS if applicableLH / FSH — track HPTA suppressionTSH, Free T3, Free T4 — thyroid health, essential on GHFasting glucose + HbA1c — metabolic health, GH insulin resistanceLipid panel (LDL, HDL, triglycerides) — AI will worsen this, monitorLiver enzymes (ALT, AST) — essential if running any oral AASBone age X-ray — every 4–6 months to track skeletal maturation vs growth velocity
If you are not monitoring bloodwork you are flying blind and have no idea if what you are doing is helping or destroying you.
Part 11 — Risks: Read This Before You Do Anything
This needs to be said clearly and seriously.
You are intervening in the most complex hormonal system in the human body during what may be its most sensitive developmental window. Most of these compounds have no safety data in healthy adolescents. The clinical data that exists is in children with diagnosed growth disorders under close medical supervision with regular monitoring.
Specific serious risks permanent endocrine disruption from AAS/AI misuse — HPTA suppression, infertility, hormonal dysregulation that does not fully recoverBone density loss from chronic E2 suppression — growing taller with structurally weaker bonesOrgan hypertrophy from excessive long-term GH — heart, kidneys, intestinesScoliosis and spinal deformity from aggressive FGFR inhibitionHepatotoxicity from oral AAS — Halotestin is seriously liver toxic, do not run it long termHypoglycemia from insulin — can cause seizures, brain damage, deathCancer risk from Wnt pathway agonists and Hedgehog activators — theoretical but real pathwaysUsing unverified gray market compounds that may be entirely bunk or contaminated with unknown substancesPsychological dependence on external hormonal manipulationBrain development effects from E2 suppression in adolescence — genuinely underresearched
The honest reality: There are no guarantees. You can take everything on this list perfectly and get zero height, or get sides with no growth. How your body responds is heavily genetic. No verified hyper-responder exists in the community. Someone who follows this thread may get 6 cm of extra height. Someone else might get organ issues and nothing else.
If you are a minor considering any of this: at minimum do this with regular bloodwork and ideally with a doctor who understands the compounds involved.
Sources
AI + GH Clinical:https://pubmed.ncbi.nlm.nih.gov/277...om/doi/abs/10.1111/j.1651-2227.1963.tb03805.x
Estrogen and Fusion:https://www.nature.com/articles/pr19992810
CXXC5 / KY19382 / Wnt:https://pmc.ncbi.nlm.nih.gov/articl...tionhttps://pubmed.ncbi.nlm.nih.gov/30971423/
FGFR Inhibitors:https://investor.bridgebio.com/news...://pmc.ncbi.nlm.nih.gov/articles/PMC12668719/
PTHrP / Abaloparatide / Vosoritide:https://www.nejm.org/doi/full/10.1056/NEJMoa1813446
AAS:https://www.jpeds.com/article/S0022...3523/https://pubmed.ncbi.nlm.nih.gov/8464656/
Tamoxifen:https://pubmed.ncbi.nlm.nih.gov/16322179/https://pubmed.ncbi.nlm.nih.gov/18348701/
SOCS2:https://www.nature.com/articles/350...blication/linked-with-missense-mutation-SOCS2
SAG21k:https://pmc.ncbi.nlm.nih.gov/articles/PMC10506518/
SCO-240:https://pubmed.ncbi.nlm.nih.gov/38549435/
This thread is for educational purposes only. Nothing here is medical advice. Everything discussed carries real risks. Do your research, get bloodwork, and if possible work with a doctor who understands what you are doing.
TAGS:
@Zagro,@Menas,@Chad ,@Typhon , @Orka rate the thread
@FutureSlayer can u take away my 90% warning high effort post
monthly costs of 12iu 5 days on and 2 days of is around 260 dollars if u find the right source thats pretty cheap if u have a job
big shout out to Choh Hao li for Hgh
Thanks bhai u might aswell rep me and I will send you a source
Omd spinal plates fuse way later u just need to use gigantism amounts of hgh and u will gain a inch or two
Aight bro I hear you
Bjt Im not sure tho Im not some knowledge god shahaha now rep me troughout this thread and I will give u tje info u need
Post isnt gpt like and I can answer u if u rep me troghiut this thread cuz I’m kyl doing it for for ko merit
What info do you have that isn’t on the thread
lile stacks and sources and how to diet when on this and all of that cuz that’s exclusively for people that rep every post of me in this thread
Heightmaxing Guide 101
Thread song:
ive been studying this topic since i learned about it and i have ordered my stack and everything is ready enough about that though tho. In this thread I will go through a couple of things like growth plates, HGH, AIs, AAS, FGFR inhibitors, and more. Some of the topics I will talk about are pretty new knowledge so don't bash on me if I am wrong cuz I'm trying my best
This thread is for educational and harm reduction purposes only. Everything discussed here carries real medical risks. I am not a doctor. Do your own research and consult a professional before touching any of this.
Part 1 — Growth Plates: The Foundation
Before you understand any protocol you need to understand what we are actually working with.
Growth plates (epiphyseal plates) are made of hyaline cartilage and sit between the epiphysis and metaphysis of your long bones. They are divided into three functional zones:
Resting Zone — sits at the top near the end of the bone. Cells here are mostly dormant and act as a reserve supply of chondrocytes, slowly feeding the zones below when needed.
Proliferative Zone — the active factory. Chondrocytes divide rapidly and stack into neat columns. Every division adds a small increment of bone length. This is where the majority of height gain actually happens.
Hypertrophic Zone — cells stop dividing and enlarge significantly. They mineralize the surrounding cartilage matrix and then undergo programmed death, with the hardened cartilage replaced by real bone. Last step before permanent ossification.
When all three zones stop functioning and fully ossify — growth is permanently over.
Key things most people get wrong:
Bone age is not the same as chronological age. A 16 year old with a bone age of 18 has almost no runway left. A 16 year old with a bone age of 13 has potentially years ahead of him. Getting a bone age X-ray is step one before any protocol, period.
Estrogen closes plates, not testosterone directly. Testosterone must convert to estrogen via aromatase to trigger epiphyseal fusion. Men with aromatase deficiency keep growing into their 30s. This single fact is the entire biological rationale for aromatase inhibitors in height protocols.
CXXC5 drives growth plate senescence. As puberty progresses a protein called CXXC5 gradually accumulates in the growth plate. It acts as a negative regulator of Wnt/β-catenin signaling — a biological stop-growing signal that builds up over time. Mice without CXXC5 showed delayed plate senescence and measurable tibial elongation (Choi et al., 2019). Estrogen directly upregulates CXXC5 via estrogen receptor alpha, which connects the AI strategy directly to this molecular mechanism.
The last plates to fuse are typically the clavicle and vertebral ring apophyses, which is why some people keep growing into their early 20s. There is often more runway than assumed.
Part 2 — HGH: The Gas Pedal
HGH is the primary driver of longitudinal bone growth but does not act alone.
The mechanism: GH stimulates the liver to produce IGF-1, IGF-1 binds receptors at the growth plate, chondrocyte proliferation and hypertrophy follows, and longitudinal growth occurs. GH also has direct local effects at the plate itself but IGF-1 is the dominant downstream signal.
Why dose matters: Clinical protocols for idiopathic short stature use roughly 0.3–0.5 mg/kg/week (1–3 IU/day). Higher doses elevate IGF-1 further but receptor saturation creates diminishing returns. People with gigantism who chronically overproduce GH do not appear to hit a hard cap on growth velocity, suggesting that in the right hormonal environment higher doses remain meaningful.
Dosing tiers:4–6 IU/day — solid starting point, meaningful IGF-1 elevation, manageable sides6–8 IU/day — more aggressive, noticeable water retention and joint effects begin12 IU/day — high end, significant side effect risk, requires full support protocol25+ IU/day — extreme territory, meaningful organ growth and metabolic risk, but for purely height u shouldnt be under 10+ ius and if u worried about getting uncanny dont worry u would need to be on 15+ iu for 10 years to become uncanny
HGH Timing (critical and often ignored):Inject on a completely empty stomach. Wait 15–30 minutes, then consume fast acting carbs and amino acids. This maximizes the GH pulse and IGF-1 response. Injecting after food — especially carbs — blunts the effect significantly because elevated insulin at time of injection competes with GH signaling. Morning fasted injection is the most common approach.
Thyroid drain — one of the most overlooked sides:HGH accelerates the conversion of T4 (inactive thyroid hormone) to T3 (active thyroid hormone). Over time this overworks the thyroid and can slow it down, producing symptoms like fatigue, feeling cold, poor recovery, brain fog, and weight gain despite eating normally. This is why thyroid function (TSH, Free T3, Free T4) should be included in all bloodwork panels on cycle. Some users add T4 supplementation proactively as support, especially at higher GH doses.
HGH side effects to monitor:Water retention and bloating (aldosterone/sodium retention)Joint pain and carpal tunnel (fluid pressure on median nerve)Insulin resistance (GH is anti-insulin by nature)Thyroid suppression at sustained high dosesOrgan growth (gut, kidneys, heart) at very high long term dosesAcromegalic features (jaw, brow, hands, feet) — takes years at high doses but irreversible
Pros:Muscle growth and improved body composition via IGF-1Fat loss through lipolysisFaster recoveryImproved skin collagen and elasticityStronger bones via increased bone mineral densityLongitudinal growth if plates are openBetter sleep quality
Part 3 — Support Supplements: Non-Negotiable
This section is essential and most people skip it. Every compound in this thread creates metabolic stress somewhere. These supplements directly counter the most common and serious side effects.
Berberine (1000–1500 mg/day, split into 2–3 doses with meals)HGH causes insulin resistance. Berberine activates AMPK (the same pathway as metformin) and directly improves insulin sensitivity. This is the most important metabolic support compound on a GH cycle. It also improves lipid profiles, reduces LDL, and has mild anti-inflammatory effects. Take with meals to avoid GI upset. Risks: GI discomfort at high doses, mild hypoglycemia if stacked aggressively with other insulin sensitizers. Do not stack with metformin without monitoring.
Acarbose (25–50 mg with carb-containing meals)Alpha-glucosidase inhibitor. Slows the digestion and absorption of carbohydrates, which blunts post-meal blood glucose spikes that GH exaggerates. Particularly useful around your post-injection carb intake. Works at the gut level so systemic side effects are minimal, but expect significant gas and bloating when you first start — this fades over 2–3 weeks as gut bacteria adapt. Risk: GI discomfort, do not use during hypoglycemic episodes as it blocks carb absorption and will prevent glucose recovery.
T4/Thyroid Support (dosing varies — get bloodwork first)As explained above, HGH drains the thyroid over time by accelerating T4 to T3 conversion. If bloodwork shows TSH rising or Free T3/T4 falling, low dose T4 supplementation (levothyroxine, 25–50 mcg/day is a common starting point) can restore balance. Do not start thyroid hormones without baseline bloodwork — supplementing when your thyroid is functioning normally can suppress natural production. Risks: palpitations, anxiety, insomnia, hyperthyroidism at excessive doses, permanent suppression of natural thyroid function if run too aggressively long term.
TUDCA (500–1000 mg/day)Tauroursodeoxycholic acid — a bile acid that directly protects liver cells from stress and apoptosis. Essential if you are running any oral AAS (Halotestin is significantly hepatotoxic). Reduces liver enzyme elevation, protects against cholestasis. Very well tolerated. Risks: mild GI effects at high doses, otherwise considered very safe.
Citrus Bergamot (500–1500 mg/day)Crashed E2 from AIs destroys your lipid profile — HDL drops, LDL rises, cardiovascular risk climbs. Citrus bergamot is one of the most evidence-backed natural compounds for improving cholesterol. It reduces LDL, raises HDL, and reduces triglycerides. Consider it mandatory if you are running an AI. Risks: very low, mild GI upset in some people.
Cod Liver Oil / Omega-3 (2–4 g EPA+DHA daily)Reduces systemic inflammation, supports cardiovascular health, improves lipid profile synergistically with bergamot, and protects joints which GH can stress via fluid retention and cartilage effects. Get a high quality molecularly distilled product to avoid heavy metal contamination. Risks: fishy burps, mild blood thinning at very high doses, avoid mega-dosing before surgery.
Vitamin D3 + K2Both are essential for bone mineralization. If you are growing bone you need adequate D3 (2000–5000 IU/day) paired with K2 (MK-7, 100–200 mcg/day) to direct calcium into bone rather than soft tissue. Deficiency in either will blunt the skeletal gains from your protocol.
Zinc (25–50 mg/day with food)Supports testosterone production, immune function, and IGF-1 signaling. Commonly depleted during intense training and hormonal manipulation. Take with food to avoid nausea. Do not exceed 50 mg/day long term without copper supplementation as zinc depletes copper.
Part 4 — Blood Glucose Management and Insulin
Why blood glucose matters on GH:GH is inherently anti-insulin — it raises blood glucose by suppressing peripheral glucose uptake. At high doses this becomes significant and unmanaged insulin resistance leads to chronic elevated blood sugar, which causes long term metabolic damage and paradoxically blunts IGF-1 signaling efficiency.
Blood glucose monitoring protocol:Get a cheap glucometer. Check fasted morning glucose and post-meal glucose. Target fasted BG under 100 mg/dL, post-meal under 140 mg/dL at 2 hours. If numbers are creeping up, increase berberine dose and add acarbose before carb meals.
The 10–15g carbs per IU rule:After injecting GH fasted and waiting 15–30 minutes, consume 10–15 grams of fast acting carbs per IU of GH to keep blood sugar stable and avoid hypoglycemia rebound. Pair with amino acids to maximize the IGF-1 anabolic window.
Lantus Insulin (long-acting, for advanced users only):Lantus (insulin glargine) is a 24-hour basal insulin. It is used in advanced stacks because insulin and IGF-1 are synergistic — insulin drives glucose and amino acids into cells creating a highly anabolic environment that multiplies the effect of elevated IGF-1 from GH. In the context of height, this means more fuel delivered to chondrocytes at exactly the time GH is signaling them to proliferate.
Typical starting dose: 5–10 IU subcutaneous, once daily, usually at night. Titrate slowly based on fasted morning glucose. Target fasted BG of 80–90 mg/dL.
This is genuinely dangerous. Read this carefully:Insulin overdose causes hypoglycemia which can cause seizures, brain damage, and death within minutes. Always have fast acting glucose (dextrose tablets, juice, regular soda) immediately accessible before every injection. Never inject Lantus and then go to sleep without someone who knows what you are doing nearby. Never use rapid acting insulin (Humalog, Novorapid) unless you have extensive experience — the margin for error is extremely small. Symptoms of hypoglycemia: shakiness, sweating, confusion, heart racing, vision changes. Treat immediately with 15–20g fast acting glucose and recheck in 15 minutes. Do not use insulin if you are not monitoring blood glucose regularly. Do not use insulin if you are alone, especially not at night.
Risks of long term insulin use: insulin resistance, weight gain, hypoglycemic episodes, dependency, lipodystrophy at injection sites.
This is the highest risk compound in any heightmaxxing stack. The potential synergy with GH/IGF-1 is real, but it should only be considered by those who fully understand glucose management and have all safety measures in place.
Part 5 — AIs (Aromatase Inhibitors): Stopping the Clock
The most clinically validated intervention in this entire thread alongside GH.
The biology: Aromatase converts testosterone to estrogen. Estrogen upregulates CXXC5, suppresses Wnt/β-catenin, and drives growth plate senescence and fusion. Block aromatase, keep E2 low, and the senescence clock slows dramatically.
A 2016 RCT (https://pubmed.ncbi.nlm.nih.gov/27710241/) and a 2025 meta-analysis (https://pmc.ncbi.nlm.nih.gov/articles/PMC12342369/) both confirmed that combining AIs with GH produces significantly greater adult height outcomes than GH alone in pubertal boys with idiopathic short stature. This is the most evidence-backed combination in heightmaxxing.
Letrozole (2.5 mg/day) — gold standard, most potent non-steroidal reversible AI. Crushes E2 to 5–15 pg/mL range. Most clinical height studies use this dose.
Anastrozole (0.5–1 mg/day) — weaker than letrozole but has more pediatric ISS trial data. Less aggressive suppression, which some argue is safer for bone density preservation.
Fulvestrant (Faslodex) — SERD, degrades estrogen receptors entirely rather than just blocking aromatase. Nuclear option. The ICI 182,780 mouse study (https://www.nature.com/articles/pr19992810) showed it can prevent estrogen-accelerated bone maturation even when E2 is present. Used in advanced protocols stacked with an AI for dual pathway blockade.
Exemestane (Aromasin, 12.5–25 mg EOD) — steroidal suicidal AI, permanently destroys aromatase molecules. Has a steroidal backbone which can behave differently from non-steroidal AIs. Some rat data showed reduced bone length. Controversial in this context — most community consensus leans toward letrozole.
Critical risks:Bone density loss — E2 is essential for bone mineralization. Chronic suppression while growing taller means potentially weaker bones. Counteract with Vitamin D3/K2, calcium, and Abaloparatide if running aggressive suppression. Lipid dysregulation — E2 is cardioprotective. Crashed E2 worsens cholesterol profile significantly. Run citrus bergamot and omega-3 mandatory. Joint pain, mood issues, libido loss. Potential neurological effects in adolescents — E2 plays a role in brain development during puberty. This is underresearched and a genuine unknown risk. Get bloodwork every 6–8 weeks minimum.
Part 6 — FGFR Inhibitors: Removing the Brake
FGFR3 is a negative regulator of bone growth — a biological brake signal in the growth plate. Blocking it allows the GH/IGF-1 gas pedal to work without interference.
The framework: HGH provides the raw IGF-1 anabolic signal (gas). FGFR3 inhibition removes the stop-growth signal (brake removal). Together: unimpeded growth velocity.
Infigratinib — oral FGFR1-3 inhibitor. RCT data in achondroplasia kids showed +1.74–2.50 cm/year extra annualized height velocity vs placebo (https://investor.bridgebio.com/news...roportionality-in-Achondroplasia/default.aspx). First drug to show statistically significant improvement in body proportionality in ACH. The problem: hitting FGFR1 and FGFR2 causes hyperphosphatemia and additional off-target toxicity. More studied than TYRA-300 but riskier.
TYRA-300 (Dabogratinib) — selective FGFR3 only inhibitor. First-in-class. Mouse data (https://insight.jci.org/articles/view/189307) showed significant increases in femur length (+3.7–5%), tibia length (+3.75–6%), and improved skeletal proportionality even in wild-type (normal) mice — not just ACH models. This is huge because it suggests benefit even without a pathological FGFR3 mutation. Spares FGFR1/2/4 so avoids the phosphate toxicity of infigratinib. Main issues: no human height trial data yet, very difficult to verify product purity from gray market sources, expensive.
Erdafitinib — pan-FGFR1-4 inhibitor, most potent but least selective. One case study showed extreme height velocity in a child on it for cancer treatment but also caused rapid overgrowth, kyphoscoliosis, and spinal deformities (https://www.sciencedirect.com/science/article/pii/S2405844024069184). Mechanism is proven but risk profile is the worst of the group. Not recommended.
Loxo-435 — highly selective FGFR3 inhibitor from Lilly. Promising alongside TYRA-300 but even less data available.
Vosoritide — CNP analog, works downstream of FGFR3 by raising cGMP and inhibiting the MAPK/ERK pathway rather than blocking the receptor directly. FDA approved for achondroplasia. RCT (https://www.nejm.org/doi/full/10.1056/NEJMoa1813446) showed +1.57 cm/year extra growth velocity vs placebo. Safer mechanism but weaker effect than direct FGFR3 blockade and degrades very fast requiring careful storage and daily injection. Expensive.
Honest reality check: Most FGFR compounds on the gray market are unverifiable. There are essentially no reputable lab tests confirming that what is sold as TYRA-300 or infigratinib actually contains what is claimed. For most people optimizing GH + letrozole will outperform spending money on potentially bunk FGFR compounds. TYRA-300 is worth pursuing only if you can verify pharmaceutical grade product.
Part 7 — AAS: The Double-Edged Sword
Complicated territory. AAS can both help and hurt height depending on what you use and when.
The problem with most AAS: When any androgen enters the bloodstream it reaches growth plate chondrocytes and binds directly to androgen receptors. These receptors accelerate terminal differentiation — telling chondrocytes to stop dividing and mature into bone faster. This happens regardless of dose. There is no low enough dose that completely avoids this effect. Aromatizable androgens compound this by also converting to estrogen, advancing bone age rapidly.
Halotestin (Fluoxymesterone) @ 2.5 mg/day — the most defensible option:Non-aromatizing. Cannot convert to estrogen. Provides direct AR stimulus at the growth plate, upregulating local IGF-1 receptor expression and making chondrocytes hypersensitive to the GH signal. Provides a pubertal growth stimulus without triggering the estrogen-mediated fusion pathway. The 1993 Moore study (https://pubmed.ncbi.nlm.nih.gov/8464656/) showed low-dose Halotestin in boys with growth delays resulted in final height +6.1 cm above predicted genetic baseline, with bone age advancing less than growth velocity. Keep cycles short — Halotestin is significantly hepatotoxic. Run TUDCA mandatory. Do not exceed 2.5 mg/day for height purposes.
Anavar (Oxandrolone) @ 2.5–5 mg/day:Mildest of the three. Has some pediatric ISS data. Low aromatization rate and reduces aromatizable substrate via negative feedback on HPTA. One study (https://www.jpeds.com/article/S0022-3476(71)80204-4/fulltext) showed increased height velocity but also accelerated skeletal age — some children in the trial lost 1.5–7.5 cm of predicted adult height. The velocity increase may not translate to better final height. More evidence than Halotestin but less favorable risk/reward for pure height purposes.
Winstrol (Stanozolol):Animal data (https://pubmed.ncbi.nlm.nih.gov/21823523/) shows direct effects on growth plate chondrocytes via estrogen receptor pathways. Less data than the other two. Not a first choice for height.
Masteron, Primobolan: Non-aromatizing, mild. Less data for height specifically but lower risk profile than Halotestin. May be useful for androgenic stimulus with lower hepatotoxicity.
Bottom line: If you use any AAS on a height protocol use the lowest effective dose of a non-aromatizing compound and stack mandatorily with an AI. Never use testosterone or aromatizable androgens without an AI. Monitor bone age every 4–6 months. The younger you are the more conservative you need to be.
Part 8 — Advanced Compounds
KY19382 — Wnt/β-catenin Reactivation:Small molecule CXXC5-DVL inhibitor. By disrupting the CXXC5-Dvl interaction it stabilizes nuclear β-catenin and reactivates Wnt signaling in the growth plate — directly reversing the senescence mechanism. Mouse data (https://pmc.ncbi.nlm.nih.gov/articles/PMC6458850/): 0.1 mg/kg daily for 10 weeks produced statistically significant tibial elongation (p<0.0005), increased proliferating chondrocytes, expanded proliferative and hypertrophic zones. Also promotes facial bone remodeling via periosteal apposition. Administration: subcutaneous injection preferred over transdermal. Caveats: all data is preclinical (mouse/cell line), no human height trials, Wnt pathway activation warrants cancer monitoring (though in cancer cell lines KY19382 showed anti-tumor effects via CDK1 suppression suggesting context-dependent behavior).
FOXO4-DRI — Senolytic Clearance:Synthetic peptide that selectively eliminates senescent cells by disrupting the FOXO4-p53 protective interaction, triggering apoptosis specifically in senescent chondrocytes. Rationale: senescent chondrocytes secrete SASP inflammatory factors (IL-6, MMPs) that create a toxic microenvironment suppressing nearby healthy chondrocytes and depleting the resting zone stem cell pool. Clearing them reduces this inflammatory burden and allows the remaining healthy chondrocytes to proliferate more freely. Highly theoretical for height in humans. No human data. Interesting mechanism but not something most people should approach casually.
SAG21k / Purmorphamine — Hedgehog Pathway:Small molecules that directly activate Smoothened (SMO) in the Hedgehog signaling pathway, bypassing normal Patched inhibition and activating Gli transcription factors. Effect: more epiphyseal stem cells multiply, chondrocyte columns thicken, growth plates become more active. Mouse data (https://pmc.ncbi.nlm.nih.gov/articles/PMC10506518/) showed strong enhancement of chondrogenesis. Major concern: Hedgehog pathway overactivation is strongly linked to cancer development. This is not a minor theoretical risk — sustained Hh pathway activation is a known driver of multiple cancer types. Only worth considering in very strategic short term windows if at all.
SOCS2 Inhibition:SOCS2 is a negative feedback regulator of GH signaling. It binds the phosphorylated GH receptor, promotes its degradation, and dampens STAT5 activation and IGF-1 production. Inhibiting SOCS2 removes this brake on GH signaling itself — essentially amplifying exogenous GH. Mice without SOCS2 grew 30–40% larger than wild-type with increased long-bone length (https://www.nature.com/articles/35016611). A human SOCS2 mutation was linked to gigantism. Risks: chronic GH/IGF-1 hypersignaling causes insulin resistance, potential organ enlargement, and IGF-1 is mitogenic meaning cancer risk with chronic elevation.
SCO-240 — Endogenous GH Amplification:Oral SSTR5 antagonist. Somatostatin normally inhibits GH release by binding SSTR5 on pituitary somatotrophs. SCO-240 blocks this, allowing the pituitary to release more GH in a physiological pulsatile pattern without affecting other pituitary hormones. Phase 1 data (https://pubmed.ncbi.nlm.nih.gov/38549435/) showed robust dose-dependent GH secretion comparable to therapeutic rhGH levels. Advantage over injected GH: mimics natural pulsatile pattern more closely. Disadvantages: only Phase 1 adult data, no height efficacy data in children yet, still carries standard GH excess risks.
Abaloparatide / Teriparatide — PTHrP Analogs:Both bind PTH1R, mimicking the natural PTHrP signal that keeps chondrocytes in the proliferative state and delays hypertrophic transition. Intermittent daily dosing expands proliferative and hypertrophic zones, increases chondrocyte columns, and prolongs the active growth window before senescence. Abaloparatide more closely mimics PTHrP's natural growth plate role, potentially providing a cleaner anabolic effect with less calcium/resorption side effects than teriparatide. Abalo also counteracts the bone density loss caused by aggressive AI use — making it arguably mandatory at the advanced level. Main risk: rat studies at high doses showed osteosarcoma signal. Clinical doses appear significantly below the threshold where this was observed but it is a real consideration for long term use.
Epitalon (Telomerase Activator):Aims to reduce the biological age of chondrocytes by activating telomerase and slowing cellular senescence. Highly speculative for height. The concept of keeping chondrocytes biologically younger for longer is mechanistically sound but human height data does not exist. Low risk profile. Subcutaneous injection.
Forskolin (20–50 mg/day)directly activates adenylyl cyclase, increases intracellular cAMP, and amplifies the mitogenic effects of IGF-1 and GH within chondrocytes. Makes the growth signal hit harder at the cellular level. Relatively accessible, low risk compared to everything else here. GI upset possible at higher doses.
Tamoxifen:SERM — selectively blocks estrogen receptors in some tissues. One study (https://pubmed.ncbi.nlm.nih.gov/16322179/) in 7 short pubertal boys showed tamoxifen significantly slowed skeletal maturation and increased predicted adult height by around 4 inches with no negative effects on puberty progression. However a rat study (https://pubmed.ncbi.nlm.nih.gov/18348701/) showed persistent shorter tibia, reduced cortical bone size, increased chondrocyte apoptosis, and lowered IGF-1. The evidence is too limited and contradictory to recommend over a proper AI. Stick to letrozole or anastrozole.
Part 9 — The Full Protocol Framework
Core (most evidence-backed):HGH: 6–12 IU/day, injected fasted, wait 15–30 min, then fast carbs plus aminosLetrozole: 2.5 mg/dayBerberine: 1000–1500 mg/day with mealsAcarbose: 25–50 mg with carb mealsTUDCA: 500–1000 mg/dayCitrus Bergamot: 500–1500 mg/dayOmega-3: 2–4 g EPA+DHA dailyVitamin D3/K2: 3000–5000 IU D3 plus 100–200 mcg K2 dailyThyroid monitoring (TSH, Free T3, Free T4) — T4 support if neededBlood glucose monitoring — target fasted under 100 mg/dL
Intermediate additions:TYRA-300 (selective FGFR3 inhibitor) — if verifiably pharmaceutical gradeHalotestin 2.5 mg/day — short cycles only, TUDCA mandatoryAbaloparatide — PTHrP signaling, bone density protection from AI useLantus insulin (5–10 IU baseline) — only with full glucose monitoring protocol and safety measures in placeForskolin 20–50 mg/day
Advanced (frontier territory, mostly preclinical data):KY19382 — Wnt/β-catenin reactivation, subcutaneousFOXO4-DRI — senolytic clearance of growth plateSCO-240 — endogenous GH amplificationSOCS2 inhibition — GH signaling amplification
For post-pubescent / closing plates:The aggressive multi-compound stack has diminishing returns once plates are fused. Focus shifts to: maximizing remaining open plates (clavicle, vertebral apophyses), spinal decompression, posture correction. KY19382 and abaloparatide may still be relevant for residual growth centers. Bone density protection becomes more important than growth velocity at this stage.
Part 10 — Bloodwork: Non-Negotiable
Get baseline before starting anything. Repeat at 6 weeks on cycle, then every 2–3 months.
What to check:IGF-1 — confirms GH is working and not bunk, tracks your responseEstradiol (E2) — confirms AI is working, avoid crashing below 5 pg/mLTotal + Free Testosterone — track suppression from AAS if applicableLH / FSH — track HPTA suppressionTSH, Free T3, Free T4 — thyroid health, essential on GHFasting glucose + HbA1c — metabolic health, GH insulin resistanceLipid panel (LDL, HDL, triglycerides) — AI will worsen this, monitorLiver enzymes (ALT, AST) — essential if running any oral AASBone age X-ray — every 4–6 months to track skeletal maturation vs growth velocity
If you are not monitoring bloodwork you are flying blind and have no idea if what you are doing is helping or destroying you.
Part 11 — Risks: Read This Before You Do Anything
This needs to be said clearly and seriously.
You are intervening in the most complex hormonal system in the human body during what may be its most sensitive developmental window. Most of these compounds have no safety data in healthy adolescents. The clinical data that exists is in children with diagnosed growth disorders under close medical supervision with regular monitoring.
Specific serious risks permanent endocrine disruption from AAS/AI misuse — HPTA suppression, infertility, hormonal dysregulation that does not fully recoverBone density loss from chronic E2 suppression — growing taller with structurally weaker bonesOrgan hypertrophy from excessive long-term GH — heart, kidneys, intestinesScoliosis and spinal deformity from aggressive FGFR inhibitionHepatotoxicity from oral AAS — Halotestin is seriously liver toxic, do not run it long termHypoglycemia from insulin — can cause seizures, brain damage, deathCancer risk from Wnt pathway agonists and Hedgehog activators — theoretical but real pathwaysUsing unverified gray market compounds that may be entirely bunk or contaminated with unknown substancesPsychological dependence on external hormonal manipulationBrain development effects from E2 suppression in adolescence — genuinely underresearched
The honest reality: There are no guarantees. You can take everything on this list perfectly and get zero height, or get sides with no growth. How your body responds is heavily genetic. No verified hyper-responder exists in the community. Someone who follows this thread may get 6 cm of extra height. Someone else might get organ issues and nothing else.
If you are a minor considering any of this: at minimum do this with regular bloodwork and ideally with a doctor who understands the compounds involved.
Sources
AI + GH Clinical:https://pubmed.ncbi.nlm.nih.gov/277...om/doi/abs/10.1111/j.1651-2227.1963.tb03805.x
Estrogen and Fusion:https://www.nature.com/articles/pr19992810
CXXC5 / KY19382 / Wnt:https://pmc.ncbi.nlm.nih.gov/articl...tionhttps://pubmed.ncbi.nlm.nih.gov/30971423/
FGFR Inhibitors:https://investor.bridgebio.com/news...://pmc.ncbi.nlm.nih.gov/articles/PMC12668719/
PTHrP / Abaloparatide / Vosoritide:https://www.nejm.org/doi/full/10.1056/NEJMoa1813446
AAS:https://www.jpeds.com/article/S0022...3523/https://pubmed.ncbi.nlm.nih.gov/8464656/
Tamoxifen:https://pubmed.ncbi.nlm.nih.gov/16322179/https://pubmed.ncbi.nlm.nih.gov/18348701/
SOCS2:https://www.nature.com/articles/350...blication/linked-with-missense-mutation-SOCS2
SAG21k:https://pmc.ncbi.nlm.nih.gov/articles/PMC10506518/
SCO-240:https://pubmed.ncbi.nlm.nih.gov/38549435/
This thread is for educational purposes only. Nothing here is medical advice. Everything discussed carries real risks. Do your research, get bloodwork, and if possible work with a doctor who understands what you are doing.
TAGS:
@Zagro,@Menas,@Chad ,@Typhon , @Orka rate the thread
@FutureSlayer can u take away my 90% warning high effort post
monthly costs of 12iu 5 days on and 2 days of is around 260 dollars if u find the right source thats pretty cheap if u have a job
big shout out to Choh Hao li for Hgh
)
Rep me while ut ut bhai and I can help uDid not read a single molecule (bookmarked tho
Alright I have nothing to lose send me your stuff
Aight wait Im gonna send it when i come home
Did you get kidnapped nigga?
Ahaha no sorry I forgot
didnt mean to say it was but just saying why it might not be getting appreciated
Heightmaxing Guide 101
Thread song:
ive been studying this topic since i learned about it and i have ordered my stack and everything is ready enough about that though tho. In this thread I will go through a couple of things like growth plates, HGH, AIs, AAS, FGFR inhibitors, and more. Some of the topics I will talk about are pretty new knowledge so don't bash on me if I am wrong cuz I'm trying my best
This thread is for educational and harm reduction purposes only. Everything discussed here carries real medical risks. I am not a doctor. Do your own research and consult a professional before touching any of this.
Part 1 — Growth Plates: The Foundation
Before you understand any protocol you need to understand what we are actually working with.
Growth plates (epiphyseal plates) are made of hyaline cartilage and sit between the epiphysis and metaphysis of your long bones. They are divided into three functional zones:
Resting Zone — sits at the top near the end of the bone. Cells here are mostly dormant and act as a reserve supply of chondrocytes, slowly feeding the zones below when needed.
Proliferative Zone — the active factory. Chondrocytes divide rapidly and stack into neat columns. Every division adds a small increment of bone length. This is where the majority of height gain actually happens.
Hypertrophic Zone — cells stop dividing and enlarge significantly. They mineralize the surrounding cartilage matrix and then undergo programmed death, with the hardened cartilage replaced by real bone. Last step before permanent ossification.
When all three zones stop functioning and fully ossify — growth is permanently over.
Key things most people get wrong:
Bone age is not the same as chronological age. A 16 year old with a bone age of 18 has almost no runway left. A 16 year old with a bone age of 13 has potentially years ahead of him. Getting a bone age X-ray is step one before any protocol, period.
Estrogen closes plates, not testosterone directly. Testosterone must convert to estrogen via aromatase to trigger epiphyseal fusion. Men with aromatase deficiency keep growing into their 30s. This single fact is the entire biological rationale for aromatase inhibitors in height protocols.
CXXC5 drives growth plate senescence. As puberty progresses a protein called CXXC5 gradually accumulates in the growth plate. It acts as a negative regulator of Wnt/β-catenin signaling — a biological stop-growing signal that builds up over time. Mice without CXXC5 showed delayed plate senescence and measurable tibial elongation (Choi et al., 2019). Estrogen directly upregulates CXXC5 via estrogen receptor alpha, which connects the AI strategy directly to this molecular mechanism.
The last plates to fuse are typically the clavicle and vertebral ring apophyses, which is why some people keep growing into their early 20s. There is often more runway than assumed.
Part 2 — HGH: The Gas Pedal
HGH is the primary driver of longitudinal bone growth but does not act alone.
The mechanism: GH stimulates the liver to produce IGF-1, IGF-1 binds receptors at the growth plate, chondrocyte proliferation and hypertrophy follows, and longitudinal growth occurs. GH also has direct local effects at the plate itself but IGF-1 is the dominant downstream signal.
Why dose matters: Clinical protocols for idiopathic short stature use roughly 0.3–0.5 mg/kg/week (1–3 IU/day). Higher doses elevate IGF-1 further but receptor saturation creates diminishing returns. People with gigantism who chronically overproduce GH do not appear to hit a hard cap on growth velocity, suggesting that in the right hormonal environment higher doses remain meaningful.
Dosing tiers:4–6 IU/day — solid starting point, meaningful IGF-1 elevation, manageable sides6–8 IU/day — more aggressive, noticeable water retention and joint effects begin12 IU/day — high end, significant side effect risk, requires full support protocol25+ IU/day — extreme territory, meaningful organ growth and metabolic risk, but for purely height u shouldnt be under 10+ ius and if u worried about getting uncanny dont worry u would need to be on 15+ iu for 10 years to become uncanny
HGH Timing (critical and often ignored):Inject on a completely empty stomach. Wait 15–30 minutes, then consume fast acting carbs and amino acids. This maximizes the GH pulse and IGF-1 response. Injecting after food — especially carbs — blunts the effect significantly because elevated insulin at time of injection competes with GH signaling. Morning fasted injection is the most common approach.
Thyroid drain — one of the most overlooked sides:HGH accelerates the conversion of T4 (inactive thyroid hormone) to T3 (active thyroid hormone). Over time this overworks the thyroid and can slow it down, producing symptoms like fatigue, feeling cold, poor recovery, brain fog, and weight gain despite eating normally. This is why thyroid function (TSH, Free T3, Free T4) should be included in all bloodwork panels on cycle. Some users add T4 supplementation proactively as support, especially at higher GH doses.
HGH side effects to monitor:Water retention and bloating (aldosterone/sodium retention)Joint pain and carpal tunnel (fluid pressure on median nerve)Insulin resistance (GH is anti-insulin by nature)Thyroid suppression at sustained high dosesOrgan growth (gut, kidneys, heart) at very high long term dosesAcromegalic features (jaw, brow, hands, feet) — takes years at high doses but irreversible
Pros:Muscle growth and improved body composition via IGF-1Fat loss through lipolysisFaster recoveryImproved skin collagen and elasticityStronger bones via increased bone mineral densityLongitudinal growth if plates are openBetter sleep quality
Part 3 — Support Supplements: Non-Negotiable
This section is essential and most people skip it. Every compound in this thread creates metabolic stress somewhere. These supplements directly counter the most common and serious side effects.
Berberine (1000–1500 mg/day, split into 2–3 doses with meals)HGH causes insulin resistance. Berberine activates AMPK (the same pathway as metformin) and directly improves insulin sensitivity. This is the most important metabolic support compound on a GH cycle. It also improves lipid profiles, reduces LDL, and has mild anti-inflammatory effects. Take with meals to avoid GI upset. Risks: GI discomfort at high doses, mild hypoglycemia if stacked aggressively with other insulin sensitizers. Do not stack with metformin without monitoring.
Acarbose (25–50 mg with carb-containing meals)Alpha-glucosidase inhibitor. Slows the digestion and absorption of carbohydrates, which blunts post-meal blood glucose spikes that GH exaggerates. Particularly useful around your post-injection carb intake. Works at the gut level so systemic side effects are minimal, but expect significant gas and bloating when you first start — this fades over 2–3 weeks as gut bacteria adapt. Risk: GI discomfort, do not use during hypoglycemic episodes as it blocks carb absorption and will prevent glucose recovery.
T4/Thyroid Support (dosing varies — get bloodwork first)As explained above, HGH drains the thyroid over time by accelerating T4 to T3 conversion. If bloodwork shows TSH rising or Free T3/T4 falling, low dose T4 supplementation (levothyroxine, 25–50 mcg/day is a common starting point) can restore balance. Do not start thyroid hormones without baseline bloodwork — supplementing when your thyroid is functioning normally can suppress natural production. Risks: palpitations, anxiety, insomnia, hyperthyroidism at excessive doses, permanent suppression of natural thyroid function if run too aggressively long term.
TUDCA (500–1000 mg/day)Tauroursodeoxycholic acid — a bile acid that directly protects liver cells from stress and apoptosis. Essential if you are running any oral AAS (Halotestin is significantly hepatotoxic). Reduces liver enzyme elevation, protects against cholestasis. Very well tolerated. Risks: mild GI effects at high doses, otherwise considered very safe.
Citrus Bergamot (500–1500 mg/day)Crashed E2 from AIs destroys your lipid profile — HDL drops, LDL rises, cardiovascular risk climbs. Citrus bergamot is one of the most evidence-backed natural compounds for improving cholesterol. It reduces LDL, raises HDL, and reduces triglycerides. Consider it mandatory if you are running an AI. Risks: very low, mild GI upset in some people.
Cod Liver Oil / Omega-3 (2–4 g EPA+DHA daily)Reduces systemic inflammation, supports cardiovascular health, improves lipid profile synergistically with bergamot, and protects joints which GH can stress via fluid retention and cartilage effects. Get a high quality molecularly distilled product to avoid heavy metal contamination. Risks: fishy burps, mild blood thinning at very high doses, avoid mega-dosing before surgery.
Vitamin D3 + K2Both are essential for bone mineralization. If you are growing bone you need adequate D3 (2000–5000 IU/day) paired with K2 (MK-7, 100–200 mcg/day) to direct calcium into bone rather than soft tissue. Deficiency in either will blunt the skeletal gains from your protocol.
Zinc (25–50 mg/day with food)Supports testosterone production, immune function, and IGF-1 signaling. Commonly depleted during intense training and hormonal manipulation. Take with food to avoid nausea. Do not exceed 50 mg/day long term without copper supplementation as zinc depletes copper.
Part 4 — Blood Glucose Management and Insulin
Why blood glucose matters on GH:GH is inherently anti-insulin — it raises blood glucose by suppressing peripheral glucose uptake. At high doses this becomes significant and unmanaged insulin resistance leads to chronic elevated blood sugar, which causes long term metabolic damage and paradoxically blunts IGF-1 signaling efficiency.
Blood glucose monitoring protocol:Get a cheap glucometer. Check fasted morning glucose and post-meal glucose. Target fasted BG under 100 mg/dL, post-meal under 140 mg/dL at 2 hours. If numbers are creeping up, increase berberine dose and add acarbose before carb meals.
The 10–15g carbs per IU rule:After injecting GH fasted and waiting 15–30 minutes, consume 10–15 grams of fast acting carbs per IU of GH to keep blood sugar stable and avoid hypoglycemia rebound. Pair with amino acids to maximize the IGF-1 anabolic window.
Lantus Insulin (long-acting, for advanced users only):Lantus (insulin glargine) is a 24-hour basal insulin. It is used in advanced stacks because insulin and IGF-1 are synergistic — insulin drives glucose and amino acids into cells creating a highly anabolic environment that multiplies the effect of elevated IGF-1 from GH. In the context of height, this means more fuel delivered to chondrocytes at exactly the time GH is signaling them to proliferate.
Typical starting dose: 5–10 IU subcutaneous, once daily, usually at night. Titrate slowly based on fasted morning glucose. Target fasted BG of 80–90 mg/dL.
This is genuinely dangerous. Read this carefully:Insulin overdose causes hypoglycemia which can cause seizures, brain damage, and death within minutes. Always have fast acting glucose (dextrose tablets, juice, regular soda) immediately accessible before every injection. Never inject Lantus and then go to sleep without someone who knows what you are doing nearby. Never use rapid acting insulin (Humalog, Novorapid) unless you have extensive experience — the margin for error is extremely small. Symptoms of hypoglycemia: shakiness, sweating, confusion, heart racing, vision changes. Treat immediately with 15–20g fast acting glucose and recheck in 15 minutes. Do not use insulin if you are not monitoring blood glucose regularly. Do not use insulin if you are alone, especially not at night.
Risks of long term insulin use: insulin resistance, weight gain, hypoglycemic episodes, dependency, lipodystrophy at injection sites.
This is the highest risk compound in any heightmaxxing stack. The potential synergy with GH/IGF-1 is real, but it should only be considered by those who fully understand glucose management and have all safety measures in place.
Part 5 — AIs (Aromatase Inhibitors): Stopping the Clock
The most clinically validated intervention in this entire thread alongside GH.
The biology: Aromatase converts testosterone to estrogen. Estrogen upregulates CXXC5, suppresses Wnt/β-catenin, and drives growth plate senescence and fusion. Block aromatase, keep E2 low, and the senescence clock slows dramatically.
A 2016 RCT (https://pubmed.ncbi.nlm.nih.gov/27710241/) and a 2025 meta-analysis (https://pmc.ncbi.nlm.nih.gov/articles/PMC12342369/) both confirmed that combining AIs with GH produces significantly greater adult height outcomes than GH alone in pubertal boys with idiopathic short stature. This is the most evidence-backed combination in heightmaxxing.
Letrozole (2.5 mg/day) — gold standard, most potent non-steroidal reversible AI. Crushes E2 to 5–15 pg/mL range. Most clinical height studies use this dose.
Anastrozole (0.5–1 mg/day) — weaker than letrozole but has more pediatric ISS trial data. Less aggressive suppression, which some argue is safer for bone density preservation.
Fulvestrant (Faslodex) — SERD, degrades estrogen receptors entirely rather than just blocking aromatase. Nuclear option. The ICI 182,780 mouse study (https://www.nature.com/articles/pr19992810) showed it can prevent estrogen-accelerated bone maturation even when E2 is present. Used in advanced protocols stacked with an AI for dual pathway blockade.
Exemestane (Aromasin, 12.5–25 mg EOD) — steroidal suicidal AI, permanently destroys aromatase molecules. Has a steroidal backbone which can behave differently from non-steroidal AIs. Some rat data showed reduced bone length. Controversial in this context — most community consensus leans toward letrozole.
Critical risks:Bone density loss — E2 is essential for bone mineralization. Chronic suppression while growing taller means potentially weaker bones. Counteract with Vitamin D3/K2, calcium, and Abaloparatide if running aggressive suppression. Lipid dysregulation — E2 is cardioprotective. Crashed E2 worsens cholesterol profile significantly. Run citrus bergamot and omega-3 mandatory. Joint pain, mood issues, libido loss. Potential neurological effects in adolescents — E2 plays a role in brain development during puberty. This is underresearched and a genuine unknown risk. Get bloodwork every 6–8 weeks minimum.
Part 6 — FGFR Inhibitors: Removing the Brake
FGFR3 is a negative regulator of bone growth — a biological brake signal in the growth plate. Blocking it allows the GH/IGF-1 gas pedal to work without interference.
The framework: HGH provides the raw IGF-1 anabolic signal (gas). FGFR3 inhibition removes the stop-growth signal (brake removal). Together: unimpeded growth velocity.
Infigratinib — oral FGFR1-3 inhibitor. RCT data in achondroplasia kids showed +1.74–2.50 cm/year extra annualized height velocity vs placebo (https://investor.bridgebio.com/news...roportionality-in-Achondroplasia/default.aspx). First drug to show statistically significant improvement in body proportionality in ACH. The problem: hitting FGFR1 and FGFR2 causes hyperphosphatemia and additional off-target toxicity. More studied than TYRA-300 but riskier.
TYRA-300 (Dabogratinib) — selective FGFR3 only inhibitor. First-in-class. Mouse data (https://insight.jci.org/articles/view/189307) showed significant increases in femur length (+3.7–5%), tibia length (+3.75–6%), and improved skeletal proportionality even in wild-type (normal) mice — not just ACH models. This is huge because it suggests benefit even without a pathological FGFR3 mutation. Spares FGFR1/2/4 so avoids the phosphate toxicity of infigratinib. Main issues: no human height trial data yet, very difficult to verify product purity from gray market sources, expensive.
Erdafitinib — pan-FGFR1-4 inhibitor, most potent but least selective. One case study showed extreme height velocity in a child on it for cancer treatment but also caused rapid overgrowth, kyphoscoliosis, and spinal deformities (https://www.sciencedirect.com/science/article/pii/S2405844024069184). Mechanism is proven but risk profile is the worst of the group. Not recommended.
Loxo-435 — highly selective FGFR3 inhibitor from Lilly. Promising alongside TYRA-300 but even less data available.
Vosoritide — CNP analog, works downstream of FGFR3 by raising cGMP and inhibiting the MAPK/ERK pathway rather than blocking the receptor directly. FDA approved for achondroplasia. RCT (https://www.nejm.org/doi/full/10.1056/NEJMoa1813446) showed +1.57 cm/year extra growth velocity vs placebo. Safer mechanism but weaker effect than direct FGFR3 blockade and degrades very fast requiring careful storage and daily injection. Expensive.
Honest reality check: Most FGFR compounds on the gray market are unverifiable. There are essentially no reputable lab tests confirming that what is sold as TYRA-300 or infigratinib actually contains what is claimed. For most people optimizing GH + letrozole will outperform spending money on potentially bunk FGFR compounds. TYRA-300 is worth pursuing only if you can verify pharmaceutical grade product.
Part 7 — AAS: The Double-Edged Sword
Complicated territory. AAS can both help and hurt height depending on what you use and when.
The problem with most AAS: When any androgen enters the bloodstream it reaches growth plate chondrocytes and binds directly to androgen receptors. These receptors accelerate terminal differentiation — telling chondrocytes to stop dividing and mature into bone faster. This happens regardless of dose. There is no low enough dose that completely avoids this effect. Aromatizable androgens compound this by also converting to estrogen, advancing bone age rapidly.
Halotestin (Fluoxymesterone) @ 2.5 mg/day — the most defensible option:Non-aromatizing. Cannot convert to estrogen. Provides direct AR stimulus at the growth plate, upregulating local IGF-1 receptor expression and making chondrocytes hypersensitive to the GH signal. Provides a pubertal growth stimulus without triggering the estrogen-mediated fusion pathway. The 1993 Moore study (https://pubmed.ncbi.nlm.nih.gov/8464656/) showed low-dose Halotestin in boys with growth delays resulted in final height +6.1 cm above predicted genetic baseline, with bone age advancing less than growth velocity. Keep cycles short — Halotestin is significantly hepatotoxic. Run TUDCA mandatory. Do not exceed 2.5 mg/day for height purposes.
Anavar (Oxandrolone) @ 2.5–5 mg/day:Mildest of the three. Has some pediatric ISS data. Low aromatization rate and reduces aromatizable substrate via negative feedback on HPTA. One study (https://www.jpeds.com/article/S0022-3476(71)80204-4/fulltext) showed increased height velocity but also accelerated skeletal age — some children in the trial lost 1.5–7.5 cm of predicted adult height. The velocity increase may not translate to better final height. More evidence than Halotestin but less favorable risk/reward for pure height purposes.
Winstrol (Stanozolol):Animal data (https://pubmed.ncbi.nlm.nih.gov/21823523/) shows direct effects on growth plate chondrocytes via estrogen receptor pathways. Less data than the other two. Not a first choice for height.
Masteron, Primobolan: Non-aromatizing, mild. Less data for height specifically but lower risk profile than Halotestin. May be useful for androgenic stimulus with lower hepatotoxicity.
Bottom line: If you use any AAS on a height protocol use the lowest effective dose of a non-aromatizing compound and stack mandatorily with an AI. Never use testosterone or aromatizable androgens without an AI. Monitor bone age every 4–6 months. The younger you are the more conservative you need to be.
Part 8 — Advanced Compounds
KY19382 — Wnt/β-catenin Reactivation:Small molecule CXXC5-DVL inhibitor. By disrupting the CXXC5-Dvl interaction it stabilizes nuclear β-catenin and reactivates Wnt signaling in the growth plate — directly reversing the senescence mechanism. Mouse data (https://pmc.ncbi.nlm.nih.gov/articles/PMC6458850/): 0.1 mg/kg daily for 10 weeks produced statistically significant tibial elongation (p<0.0005), increased proliferating chondrocytes, expanded proliferative and hypertrophic zones. Also promotes facial bone remodeling via periosteal apposition. Administration: subcutaneous injection preferred over transdermal. Caveats: all data is preclinical (mouse/cell line), no human height trials, Wnt pathway activation warrants cancer monitoring (though in cancer cell lines KY19382 showed anti-tumor effects via CDK1 suppression suggesting context-dependent behavior).
FOXO4-DRI — Senolytic Clearance:Synthetic peptide that selectively eliminates senescent cells by disrupting the FOXO4-p53 protective interaction, triggering apoptosis specifically in senescent chondrocytes. Rationale: senescent chondrocytes secrete SASP inflammatory factors (IL-6, MMPs) that create a toxic microenvironment suppressing nearby healthy chondrocytes and depleting the resting zone stem cell pool. Clearing them reduces this inflammatory burden and allows the remaining healthy chondrocytes to proliferate more freely. Highly theoretical for height in humans. No human data. Interesting mechanism but not something most people should approach casually.
SAG21k / Purmorphamine — Hedgehog Pathway:Small molecules that directly activate Smoothened (SMO) in the Hedgehog signaling pathway, bypassing normal Patched inhibition and activating Gli transcription factors. Effect: more epiphyseal stem cells multiply, chondrocyte columns thicken, growth plates become more active. Mouse data (https://pmc.ncbi.nlm.nih.gov/articles/PMC10506518/) showed strong enhancement of chondrogenesis. Major concern: Hedgehog pathway overactivation is strongly linked to cancer development. This is not a minor theoretical risk — sustained Hh pathway activation is a known driver of multiple cancer types. Only worth considering in very strategic short term windows if at all.
SOCS2 Inhibition:SOCS2 is a negative feedback regulator of GH signaling. It binds the phosphorylated GH receptor, promotes its degradation, and dampens STAT5 activation and IGF-1 production. Inhibiting SOCS2 removes this brake on GH signaling itself — essentially amplifying exogenous GH. Mice without SOCS2 grew 30–40% larger than wild-type with increased long-bone length (https://www.nature.com/articles/35016611). A human SOCS2 mutation was linked to gigantism. Risks: chronic GH/IGF-1 hypersignaling causes insulin resistance, potential organ enlargement, and IGF-1 is mitogenic meaning cancer risk with chronic elevation.
SCO-240 — Endogenous GH Amplification:Oral SSTR5 antagonist. Somatostatin normally inhibits GH release by binding SSTR5 on pituitary somatotrophs. SCO-240 blocks this, allowing the pituitary to release more GH in a physiological pulsatile pattern without affecting other pituitary hormones. Phase 1 data (https://pubmed.ncbi.nlm.nih.gov/38549435/) showed robust dose-dependent GH secretion comparable to therapeutic rhGH levels. Advantage over injected GH: mimics natural pulsatile pattern more closely. Disadvantages: only Phase 1 adult data, no height efficacy data in children yet, still carries standard GH excess risks.
Abaloparatide / Teriparatide — PTHrP Analogs:Both bind PTH1R, mimicking the natural PTHrP signal that keeps chondrocytes in the proliferative state and delays hypertrophic transition. Intermittent daily dosing expands proliferative and hypertrophic zones, increases chondrocyte columns, and prolongs the active growth window before senescence. Abaloparatide more closely mimics PTHrP's natural growth plate role, potentially providing a cleaner anabolic effect with less calcium/resorption side effects than teriparatide. Abalo also counteracts the bone density loss caused by aggressive AI use — making it arguably mandatory at the advanced level. Main risk: rat studies at high doses showed osteosarcoma signal. Clinical doses appear significantly below the threshold where this was observed but it is a real consideration for long term use.
Epitalon (Telomerase Activator):Aims to reduce the biological age of chondrocytes by activating telomerase and slowing cellular senescence. Highly speculative for height. The concept of keeping chondrocytes biologically younger for longer is mechanistically sound but human height data does not exist. Low risk profile. Subcutaneous injection.
Forskolin (20–50 mg/day)directly activates adenylyl cyclase, increases intracellular cAMP, and amplifies the mitogenic effects of IGF-1 and GH within chondrocytes. Makes the growth signal hit harder at the cellular level. Relatively accessible, low risk compared to everything else here. GI upset possible at higher doses.
Tamoxifen:SERM — selectively blocks estrogen receptors in some tissues. One study (https://pubmed.ncbi.nlm.nih.gov/16322179/) in 7 short pubertal boys showed tamoxifen significantly slowed skeletal maturation and increased predicted adult height by around 4 inches with no negative effects on puberty progression. However a rat study (https://pubmed.ncbi.nlm.nih.gov/18348701/) showed persistent shorter tibia, reduced cortical bone size, increased chondrocyte apoptosis, and lowered IGF-1. The evidence is too limited and contradictory to recommend over a proper AI. Stick to letrozole or anastrozole.
Part 9 — The Full Protocol Framework
Core (most evidence-backed):HGH: 6–12 IU/day, injected fasted, wait 15–30 min, then fast carbs plus aminosLetrozole: 2.5 mg/dayBerberine: 1000–1500 mg/day with mealsAcarbose: 25–50 mg with carb mealsTUDCA: 500–1000 mg/dayCitrus Bergamot: 500–1500 mg/dayOmega-3: 2–4 g EPA+DHA dailyVitamin D3/K2: 3000–5000 IU D3 plus 100–200 mcg K2 dailyThyroid monitoring (TSH, Free T3, Free T4) — T4 support if neededBlood glucose monitoring — target fasted under 100 mg/dL
Intermediate additions:TYRA-300 (selective FGFR3 inhibitor) — if verifiably pharmaceutical gradeHalotestin 2.5 mg/day — short cycles only, TUDCA mandatoryAbaloparatide — PTHrP signaling, bone density protection from AI useLantus insulin (5–10 IU baseline) — only with full glucose monitoring protocol and safety measures in placeForskolin 20–50 mg/day
Advanced (frontier territory, mostly preclinical data):KY19382 — Wnt/β-catenin reactivation, subcutaneousFOXO4-DRI — senolytic clearance of growth plateSCO-240 — endogenous GH amplificationSOCS2 inhibition — GH signaling amplification
For post-pubescent / closing plates:The aggressive multi-compound stack has diminishing returns once plates are fused. Focus shifts to: maximizing remaining open plates (clavicle, vertebral apophyses), spinal decompression, posture correction. KY19382 and abaloparatide may still be relevant for residual growth centers. Bone density protection becomes more important than growth velocity at this stage.
Part 10 — Bloodwork: Non-Negotiable
Get baseline before starting anything. Repeat at 6 weeks on cycle, then every 2–3 months.
What to check:IGF-1 — confirms GH is working and not bunk, tracks your responseEstradiol (E2) — confirms AI is working, avoid crashing below 5 pg/mLTotal + Free Testosterone — track suppression from AAS if applicableLH / FSH — track HPTA suppressionTSH, Free T3, Free T4 — thyroid health, essential on GHFasting glucose + HbA1c — metabolic health, GH insulin resistanceLipid panel (LDL, HDL, triglycerides) — AI will worsen this, monitorLiver enzymes (ALT, AST) — essential if running any oral AASBone age X-ray — every 4–6 months to track skeletal maturation vs growth velocity
If you are not monitoring bloodwork you are flying blind and have no idea if what you are doing is helping or destroying you.
Part 11 — Risks: Read This Before You Do Anything
This needs to be said clearly and seriously.
You are intervening in the most complex hormonal system in the human body during what may be its most sensitive developmental window. Most of these compounds have no safety data in healthy adolescents. The clinical data that exists is in children with diagnosed growth disorders under close medical supervision with regular monitoring.
Specific serious risks permanent endocrine disruption from AAS/AI misuse — HPTA suppression, infertility, hormonal dysregulation that does not fully recoverBone density loss from chronic E2 suppression — growing taller with structurally weaker bonesOrgan hypertrophy from excessive long-term GH — heart, kidneys, intestinesScoliosis and spinal deformity from aggressive FGFR inhibitionHepatotoxicity from oral AAS — Halotestin is seriously liver toxic, do not run it long termHypoglycemia from insulin — can cause seizures, brain damage, deathCancer risk from Wnt pathway agonists and Hedgehog activators — theoretical but real pathwaysUsing unverified gray market compounds that may be entirely bunk or contaminated with unknown substancesPsychological dependence on external hormonal manipulationBrain development effects from E2 suppression in adolescence — genuinely underresearched
The honest reality: There are no guarantees. You can take everything on this list perfectly and get zero height, or get sides with no growth. How your body responds is heavily genetic. No verified hyper-responder exists in the community. Someone who follows this thread may get 6 cm of extra height. Someone else might get organ issues and nothing else.
If you are a minor considering any of this: at minimum do this with regular bloodwork and ideally with a doctor who understands the compounds involved.
Sources
AI + GH Clinical:https://pubmed.ncbi.nlm.nih.gov/277...om/doi/abs/10.1111/j.1651-2227.1963.tb03805.x
Estrogen and Fusion:https://www.nature.com/articles/pr19992810
CXXC5 / KY19382 / Wnt:https://pmc.ncbi.nlm.nih.gov/articl...tionhttps://pubmed.ncbi.nlm.nih.gov/30971423/
FGFR Inhibitors:https://investor.bridgebio.com/news...://pmc.ncbi.nlm.nih.gov/articles/PMC12668719/
PTHrP / Abaloparatide / Vosoritide:https://www.nejm.org/doi/full/10.1056/NEJMoa1813446
AAS:https://www.jpeds.com/article/S0022...3523/https://pubmed.ncbi.nlm.nih.gov/8464656/
Tamoxifen:https://pubmed.ncbi.nlm.nih.gov/16322179/https://pubmed.ncbi.nlm.nih.gov/18348701/
SOCS2:https://www.nature.com/articles/350...blication/linked-with-missense-mutation-SOCS2
SAG21k:https://pmc.ncbi.nlm.nih.gov/articles/PMC10506518/
SCO-240:https://pubmed.ncbi.nlm.nih.gov/38549435/
This thread is for educational purposes only. Nothing here is medical advice. Everything discussed carries real risks. Do your research, get bloodwork, and if possible work with a doctor who understands what you are doing.
TAGS:
@Zagro,@Menas,@Chad ,@Typhon , @Orka rate the thread
@FutureSlayer can u take away my 90% warning high effort post
monthly costs of 12iu 5 days on and 2 days of is around 260 dollars if u find the right source thats pretty cheap if u have a job
big shout out to Choh Hao li for Hgh
Heightmaxing Guide 101
Thread song:
ive been studying this topic since i learned about it and i have ordered my stack and everything is ready enough about that though tho. In this thread I will go through a couple of things like growth plates, HGH, AIs, AAS, FGFR inhibitors, and more. Some of the topics I will talk about are pretty new knowledge so don't bash on me if I am wrong cuz I'm trying my best
This thread is for educational and harm reduction purposes only. Everything discussed here carries real medical risks. I am not a doctor. Do your own research and consult a professional before touching any of this.
Part 1 — Growth Plates: The Foundation
Before you understand any protocol you need to understand what we are actually working with.
Growth plates (epiphyseal plates) are made of hyaline cartilage and sit between the epiphysis and metaphysis of your long bones. They are divided into three functional zones:
Resting Zone — sits at the top near the end of the bone. Cells here are mostly dormant and act as a reserve supply of chondrocytes, slowly feeding the zones below when needed.
Proliferative Zone — the active factory. Chondrocytes divide rapidly and stack into neat columns. Every division adds a small increment of bone length. This is where the majority of height gain actually happens.
Hypertrophic Zone — cells stop dividing and enlarge significantly. They mineralize the surrounding cartilage matrix and then undergo programmed death, with the hardened cartilage replaced by real bone. Last step before permanent ossification.
When all three zones stop functioning and fully ossify — growth is permanently over.
Key things most people get wrong:
Bone age is not the same as chronological age. A 16 year old with a bone age of 18 has almost no runway left. A 16 year old with a bone age of 13 has potentially years ahead of him. Getting a bone age X-ray is step one before any protocol, period.
Estrogen closes plates, not testosterone directly. Testosterone must convert to estrogen via aromatase to trigger epiphyseal fusion. Men with aromatase deficiency keep growing into their 30s. This single fact is the entire biological rationale for aromatase inhibitors in height protocols.
CXXC5 drives growth plate senescence. As puberty progresses a protein called CXXC5 gradually accumulates in the growth plate. It acts as a negative regulator of Wnt/β-catenin signaling — a biological stop-growing signal that builds up over time. Mice without CXXC5 showed delayed plate senescence and measurable tibial elongation (Choi et al., 2019). Estrogen directly upregulates CXXC5 via estrogen receptor alpha, which connects the AI strategy directly to this molecular mechanism.
The last plates to fuse are typically the clavicle and vertebral ring apophyses, which is why some people keep growing into their early 20s. There is often more runway than assumed.
Part 2 — HGH: The Gas Pedal
HGH is the primary driver of longitudinal bone growth but does not act alone.
The mechanism: GH stimulates the liver to produce IGF-1, IGF-1 binds receptors at the growth plate, chondrocyte proliferation and hypertrophy follows, and longitudinal growth occurs. GH also has direct local effects at the plate itself but IGF-1 is the dominant downstream signal.
Why dose matters: Clinical protocols for idiopathic short stature use roughly 0.3–0.5 mg/kg/week (1–3 IU/day). Higher doses elevate IGF-1 further but receptor saturation creates diminishing returns. People with gigantism who chronically overproduce GH do not appear to hit a hard cap on growth velocity, suggesting that in the right hormonal environment higher doses remain meaningful.
Dosing tiers:4–6 IU/day — solid starting point, meaningful IGF-1 elevation, manageable sides6–8 IU/day — more aggressive, noticeable water retention and joint effects begin12 IU/day — high end, significant side effect risk, requires full support protocol25+ IU/day — extreme territory, meaningful organ growth and metabolic risk, but for purely height u shouldnt be under 10+ ius and if u worried about getting uncanny dont worry u would need to be on 15+ iu for 10 years to become uncanny
HGH Timing (critical and often ignored):Inject on a completely empty stomach. Wait 15–30 minutes, then consume fast acting carbs and amino acids. This maximizes the GH pulse and IGF-1 response. Injecting after food — especially carbs — blunts the effect significantly because elevated insulin at time of injection competes with GH signaling. Morning fasted injection is the most common approach.
Thyroid drain — one of the most overlooked sides:HGH accelerates the conversion of T4 (inactive thyroid hormone) to T3 (active thyroid hormone). Over time this overworks the thyroid and can slow it down, producing symptoms like fatigue, feeling cold, poor recovery, brain fog, and weight gain despite eating normally. This is why thyroid function (TSH, Free T3, Free T4) should be included in all bloodwork panels on cycle. Some users add T4 supplementation proactively as support, especially at higher GH doses.
HGH side effects to monitor:Water retention and bloating (aldosterone/sodium retention)Joint pain and carpal tunnel (fluid pressure on median nerve)Insulin resistance (GH is anti-insulin by nature)Thyroid suppression at sustained high dosesOrgan growth (gut, kidneys, heart) at very high long term dosesAcromegalic features (jaw, brow, hands, feet) — takes years at high doses but irreversible
Pros:Muscle growth and improved body composition via IGF-1Fat loss through lipolysisFaster recoveryImproved skin collagen and elasticityStronger bones via increased bone mineral densityLongitudinal growth if plates are openBetter sleep quality
Part 3 — Support Supplements: Non-Negotiable
This section is essential and most people skip it. Every compound in this thread creates metabolic stress somewhere. These supplements directly counter the most common and serious side effects.
Berberine (1000–1500 mg/day, split into 2–3 doses with meals)HGH causes insulin resistance. Berberine activates AMPK (the same pathway as metformin) and directly improves insulin sensitivity. This is the most important metabolic support compound on a GH cycle. It also improves lipid profiles, reduces LDL, and has mild anti-inflammatory effects. Take with meals to avoid GI upset. Risks: GI discomfort at high doses, mild hypoglycemia if stacked aggressively with other insulin sensitizers. Do not stack with metformin without monitoring.
Acarbose (25–50 mg with carb-containing meals)Alpha-glucosidase inhibitor. Slows the digestion and absorption of carbohydrates, which blunts post-meal blood glucose spikes that GH exaggerates. Particularly useful around your post-injection carb intake. Works at the gut level so systemic side effects are minimal, but expect significant gas and bloating when you first start — this fades over 2–3 weeks as gut bacteria adapt. Risk: GI discomfort, do not use during hypoglycemic episodes as it blocks carb absorption and will prevent glucose recovery.
T4/Thyroid Support (dosing varies — get bloodwork first)As explained above, HGH drains the thyroid over time by accelerating T4 to T3 conversion. If bloodwork shows TSH rising or Free T3/T4 falling, low dose T4 supplementation (levothyroxine, 25–50 mcg/day is a common starting point) can restore balance. Do not start thyroid hormones without baseline bloodwork — supplementing when your thyroid is functioning normally can suppress natural production. Risks: palpitations, anxiety, insomnia, hyperthyroidism at excessive doses, permanent suppression of natural thyroid function if run too aggressively long term.
TUDCA (500–1000 mg/day)Tauroursodeoxycholic acid — a bile acid that directly protects liver cells from stress and apoptosis. Essential if you are running any oral AAS (Halotestin is significantly hepatotoxic). Reduces liver enzyme elevation, protects against cholestasis. Very well tolerated. Risks: mild GI effects at high doses, otherwise considered very safe.
Citrus Bergamot (500–1500 mg/day)Crashed E2 from AIs destroys your lipid profile — HDL drops, LDL rises, cardiovascular risk climbs. Citrus bergamot is one of the most evidence-backed natural compounds for improving cholesterol. It reduces LDL, raises HDL, and reduces triglycerides. Consider it mandatory if you are running an AI. Risks: very low, mild GI upset in some people.
Cod Liver Oil / Omega-3 (2–4 g EPA+DHA daily)Reduces systemic inflammation, supports cardiovascular health, improves lipid profile synergistically with bergamot, and protects joints which GH can stress via fluid retention and cartilage effects. Get a high quality molecularly distilled product to avoid heavy metal contamination. Risks: fishy burps, mild blood thinning at very high doses, avoid mega-dosing before surgery.
Vitamin D3 + K2Both are essential for bone mineralization. If you are growing bone you need adequate D3 (2000–5000 IU/day) paired with K2 (MK-7, 100–200 mcg/day) to direct calcium into bone rather than soft tissue. Deficiency in either will blunt the skeletal gains from your protocol.
Zinc (25–50 mg/day with food)Supports testosterone production, immune function, and IGF-1 signaling. Commonly depleted during intense training and hormonal manipulation. Take with food to avoid nausea. Do not exceed 50 mg/day long term without copper supplementation as zinc depletes copper.
Part 4 — Blood Glucose Management and Insulin
Why blood glucose matters on GH:GH is inherently anti-insulin — it raises blood glucose by suppressing peripheral glucose uptake. At high doses this becomes significant and unmanaged insulin resistance leads to chronic elevated blood sugar, which causes long term metabolic damage and paradoxically blunts IGF-1 signaling efficiency.
Blood glucose monitoring protocol:Get a cheap glucometer. Check fasted morning glucose and post-meal glucose. Target fasted BG under 100 mg/dL, post-meal under 140 mg/dL at 2 hours. If numbers are creeping up, increase berberine dose and add acarbose before carb meals.
The 10–15g carbs per IU rule:After injecting GH fasted and waiting 15–30 minutes, consume 10–15 grams of fast acting carbs per IU of GH to keep blood sugar stable and avoid hypoglycemia rebound. Pair with amino acids to maximize the IGF-1 anabolic window.
Lantus Insulin (long-acting, for advanced users only):Lantus (insulin glargine) is a 24-hour basal insulin. It is used in advanced stacks because insulin and IGF-1 are synergistic — insulin drives glucose and amino acids into cells creating a highly anabolic environment that multiplies the effect of elevated IGF-1 from GH. In the context of height, this means more fuel delivered to chondrocytes at exactly the time GH is signaling them to proliferate.
Typical starting dose: 5–10 IU subcutaneous, once daily, usually at night. Titrate slowly based on fasted morning glucose. Target fasted BG of 80–90 mg/dL.
This is genuinely dangerous. Read this carefully:Insulin overdose causes hypoglycemia which can cause seizures, brain damage, and death within minutes. Always have fast acting glucose (dextrose tablets, juice, regular soda) immediately accessible before every injection. Never inject Lantus and then go to sleep without someone who knows what you are doing nearby. Never use rapid acting insulin (Humalog, Novorapid) unless you have extensive experience — the margin for error is extremely small. Symptoms of hypoglycemia: shakiness, sweating, confusion, heart racing, vision changes. Treat immediately with 15–20g fast acting glucose and recheck in 15 minutes. Do not use insulin if you are not monitoring blood glucose regularly. Do not use insulin if you are alone, especially not at night.
Risks of long term insulin use: insulin resistance, weight gain, hypoglycemic episodes, dependency, lipodystrophy at injection sites.
This is the highest risk compound in any heightmaxxing stack. The potential synergy with GH/IGF-1 is real, but it should only be considered by those who fully understand glucose management and have all safety measures in place.
Part 5 — AIs (Aromatase Inhibitors): Stopping the Clock
The most clinically validated intervention in this entire thread alongside GH.
The biology: Aromatase converts testosterone to estrogen. Estrogen upregulates CXXC5, suppresses Wnt/β-catenin, and drives growth plate senescence and fusion. Block aromatase, keep E2 low, and the senescence clock slows dramatically.
A 2016 RCT (https://pubmed.ncbi.nlm.nih.gov/27710241/) and a 2025 meta-analysis (https://pmc.ncbi.nlm.nih.gov/articles/PMC12342369/) both confirmed that combining AIs with GH produces significantly greater adult height outcomes than GH alone in pubertal boys with idiopathic short stature. This is the most evidence-backed combination in heightmaxxing.
Letrozole (2.5 mg/day) — gold standard, most potent non-steroidal reversible AI. Crushes E2 to 5–15 pg/mL range. Most clinical height studies use this dose.
Anastrozole (0.5–1 mg/day) — weaker than letrozole but has more pediatric ISS trial data. Less aggressive suppression, which some argue is safer for bone density preservation.
Fulvestrant (Faslodex) — SERD, degrades estrogen receptors entirely rather than just blocking aromatase. Nuclear option. The ICI 182,780 mouse study (https://www.nature.com/articles/pr19992810) showed it can prevent estrogen-accelerated bone maturation even when E2 is present. Used in advanced protocols stacked with an AI for dual pathway blockade.
Exemestane (Aromasin, 12.5–25 mg EOD) — steroidal suicidal AI, permanently destroys aromatase molecules. Has a steroidal backbone which can behave differently from non-steroidal AIs. Some rat data showed reduced bone length. Controversial in this context — most community consensus leans toward letrozole.
Critical risks:Bone density loss — E2 is essential for bone mineralization. Chronic suppression while growing taller means potentially weaker bones. Counteract with Vitamin D3/K2, calcium, and Abaloparatide if running aggressive suppression. Lipid dysregulation — E2 is cardioprotective. Crashed E2 worsens cholesterol profile significantly. Run citrus bergamot and omega-3 mandatory. Joint pain, mood issues, libido loss. Potential neurological effects in adolescents — E2 plays a role in brain development during puberty. This is underresearched and a genuine unknown risk. Get bloodwork every 6–8 weeks minimum.
Part 6 — FGFR Inhibitors: Removing the Brake
FGFR3 is a negative regulator of bone growth — a biological brake signal in the growth plate. Blocking it allows the GH/IGF-1 gas pedal to work without interference.
The framework: HGH provides the raw IGF-1 anabolic signal (gas). FGFR3 inhibition removes the stop-growth signal (brake removal). Together: unimpeded growth velocity.
Infigratinib — oral FGFR1-3 inhibitor. RCT data in achondroplasia kids showed +1.74–2.50 cm/year extra annualized height velocity vs placebo (https://investor.bridgebio.com/news...roportionality-in-Achondroplasia/default.aspx). First drug to show statistically significant improvement in body proportionality in ACH. The problem: hitting FGFR1 and FGFR2 causes hyperphosphatemia and additional off-target toxicity. More studied than TYRA-300 but riskier.
TYRA-300 (Dabogratinib) — selective FGFR3 only inhibitor. First-in-class. Mouse data (https://insight.jci.org/articles/view/189307) showed significant increases in femur length (+3.7–5%), tibia length (+3.75–6%), and improved skeletal proportionality even in wild-type (normal) mice — not just ACH models. This is huge because it suggests benefit even without a pathological FGFR3 mutation. Spares FGFR1/2/4 so avoids the phosphate toxicity of infigratinib. Main issues: no human height trial data yet, very difficult to verify product purity from gray market sources, expensive.
Erdafitinib — pan-FGFR1-4 inhibitor, most potent but least selective. One case study showed extreme height velocity in a child on it for cancer treatment but also caused rapid overgrowth, kyphoscoliosis, and spinal deformities (https://www.sciencedirect.com/science/article/pii/S2405844024069184). Mechanism is proven but risk profile is the worst of the group. Not recommended.
Loxo-435 — highly selective FGFR3 inhibitor from Lilly. Promising alongside TYRA-300 but even less data available.
Vosoritide — CNP analog, works downstream of FGFR3 by raising cGMP and inhibiting the MAPK/ERK pathway rather than blocking the receptor directly. FDA approved for achondroplasia. RCT (https://www.nejm.org/doi/full/10.1056/NEJMoa1813446) showed +1.57 cm/year extra growth velocity vs placebo. Safer mechanism but weaker effect than direct FGFR3 blockade and degrades very fast requiring careful storage and daily injection. Expensive.
Honest reality check: Most FGFR compounds on the gray market are unverifiable. There are essentially no reputable lab tests confirming that what is sold as TYRA-300 or infigratinib actually contains what is claimed. For most people optimizing GH + letrozole will outperform spending money on potentially bunk FGFR compounds. TYRA-300 is worth pursuing only if you can verify pharmaceutical grade product.
Part 7 — AAS: The Double-Edged Sword
Complicated territory. AAS can both help and hurt height depending on what you use and when.
The problem with most AAS: When any androgen enters the bloodstream it reaches growth plate chondrocytes and binds directly to androgen receptors. These receptors accelerate terminal differentiation — telling chondrocytes to stop dividing and mature into bone faster. This happens regardless of dose. There is no low enough dose that completely avoids this effect. Aromatizable androgens compound this by also converting to estrogen, advancing bone age rapidly.
Halotestin (Fluoxymesterone) @ 2.5 mg/day — the most defensible option:Non-aromatizing. Cannot convert to estrogen. Provides direct AR stimulus at the growth plate, upregulating local IGF-1 receptor expression and making chondrocytes hypersensitive to the GH signal. Provides a pubertal growth stimulus without triggering the estrogen-mediated fusion pathway. The 1993 Moore study (https://pubmed.ncbi.nlm.nih.gov/8464656/) showed low-dose Halotestin in boys with growth delays resulted in final height +6.1 cm above predicted genetic baseline, with bone age advancing less than growth velocity. Keep cycles short — Halotestin is significantly hepatotoxic. Run TUDCA mandatory. Do not exceed 2.5 mg/day for height purposes.
Anavar (Oxandrolone) @ 2.5–5 mg/day:Mildest of the three. Has some pediatric ISS data. Low aromatization rate and reduces aromatizable substrate via negative feedback on HPTA. One study (https://www.jpeds.com/article/S0022-3476(71)80204-4/fulltext) showed increased height velocity but also accelerated skeletal age — some children in the trial lost 1.5–7.5 cm of predicted adult height. The velocity increase may not translate to better final height. More evidence than Halotestin but less favorable risk/reward for pure height purposes.
Winstrol (Stanozolol):Animal data (https://pubmed.ncbi.nlm.nih.gov/21823523/) shows direct effects on growth plate chondrocytes via estrogen receptor pathways. Less data than the other two. Not a first choice for height.
Masteron, Primobolan: Non-aromatizing, mild. Less data for height specifically but lower risk profile than Halotestin. May be useful for androgenic stimulus with lower hepatotoxicity.
Bottom line: If you use any AAS on a height protocol use the lowest effective dose of a non-aromatizing compound and stack mandatorily with an AI. Never use testosterone or aromatizable androgens without an AI. Monitor bone age every 4–6 months. The younger you are the more conservative you need to be.
Part 8 — Advanced Compounds
KY19382 — Wnt/β-catenin Reactivation:Small molecule CXXC5-DVL inhibitor. By disrupting the CXXC5-Dvl interaction it stabilizes nuclear β-catenin and reactivates Wnt signaling in the growth plate — directly reversing the senescence mechanism. Mouse data (https://pmc.ncbi.nlm.nih.gov/articles/PMC6458850/): 0.1 mg/kg daily for 10 weeks produced statistically significant tibial elongation (p<0.0005), increased proliferating chondrocytes, expanded proliferative and hypertrophic zones. Also promotes facial bone remodeling via periosteal apposition. Administration: subcutaneous injection preferred over transdermal. Caveats: all data is preclinical (mouse/cell line), no human height trials, Wnt pathway activation warrants cancer monitoring (though in cancer cell lines KY19382 showed anti-tumor effects via CDK1 suppression suggesting context-dependent behavior).
FOXO4-DRI — Senolytic Clearance:Synthetic peptide that selectively eliminates senescent cells by disrupting the FOXO4-p53 protective interaction, triggering apoptosis specifically in senescent chondrocytes. Rationale: senescent chondrocytes secrete SASP inflammatory factors (IL-6, MMPs) that create a toxic microenvironment suppressing nearby healthy chondrocytes and depleting the resting zone stem cell pool. Clearing them reduces this inflammatory burden and allows the remaining healthy chondrocytes to proliferate more freely. Highly theoretical for height in humans. No human data. Interesting mechanism but not something most people should approach casually.
SAG21k / Purmorphamine — Hedgehog Pathway:Small molecules that directly activate Smoothened (SMO) in the Hedgehog signaling pathway, bypassing normal Patched inhibition and activating Gli transcription factors. Effect: more epiphyseal stem cells multiply, chondrocyte columns thicken, growth plates become more active. Mouse data (https://pmc.ncbi.nlm.nih.gov/articles/PMC10506518/) showed strong enhancement of chondrogenesis. Major concern: Hedgehog pathway overactivation is strongly linked to cancer development. This is not a minor theoretical risk — sustained Hh pathway activation is a known driver of multiple cancer types. Only worth considering in very strategic short term windows if at all.
SOCS2 Inhibition:SOCS2 is a negative feedback regulator of GH signaling. It binds the phosphorylated GH receptor, promotes its degradation, and dampens STAT5 activation and IGF-1 production. Inhibiting SOCS2 removes this brake on GH signaling itself — essentially amplifying exogenous GH. Mice without SOCS2 grew 30–40% larger than wild-type with increased long-bone length (https://www.nature.com/articles/35016611). A human SOCS2 mutation was linked to gigantism. Risks: chronic GH/IGF-1 hypersignaling causes insulin resistance, potential organ enlargement, and IGF-1 is mitogenic meaning cancer risk with chronic elevation.
SCO-240 — Endogenous GH Amplification:Oral SSTR5 antagonist. Somatostatin normally inhibits GH release by binding SSTR5 on pituitary somatotrophs. SCO-240 blocks this, allowing the pituitary to release more GH in a physiological pulsatile pattern without affecting other pituitary hormones. Phase 1 data (https://pubmed.ncbi.nlm.nih.gov/38549435/) showed robust dose-dependent GH secretion comparable to therapeutic rhGH levels. Advantage over injected GH: mimics natural pulsatile pattern more closely. Disadvantages: only Phase 1 adult data, no height efficacy data in children yet, still carries standard GH excess risks.
Abaloparatide / Teriparatide — PTHrP Analogs:Both bind PTH1R, mimicking the natural PTHrP signal that keeps chondrocytes in the proliferative state and delays hypertrophic transition. Intermittent daily dosing expands proliferative and hypertrophic zones, increases chondrocyte columns, and prolongs the active growth window before senescence. Abaloparatide more closely mimics PTHrP's natural growth plate role, potentially providing a cleaner anabolic effect with less calcium/resorption side effects than teriparatide. Abalo also counteracts the bone density loss caused by aggressive AI use — making it arguably mandatory at the advanced level. Main risk: rat studies at high doses showed osteosarcoma signal. Clinical doses appear significantly below the threshold where this was observed but it is a real consideration for long term use.
Epitalon (Telomerase Activator):Aims to reduce the biological age of chondrocytes by activating telomerase and slowing cellular senescence. Highly speculative for height. The concept of keeping chondrocytes biologically younger for longer is mechanistically sound but human height data does not exist. Low risk profile. Subcutaneous injection.
Forskolin (20–50 mg/day)directly activates adenylyl cyclase, increases intracellular cAMP, and amplifies the mitogenic effects of IGF-1 and GH within chondrocytes. Makes the growth signal hit harder at the cellular level. Relatively accessible, low risk compared to everything else here. GI upset possible at higher doses.
Tamoxifen:SERM — selectively blocks estrogen receptors in some tissues. One study (https://pubmed.ncbi.nlm.nih.gov/16322179/) in 7 short pubertal boys showed tamoxifen significantly slowed skeletal maturation and increased predicted adult height by around 4 inches with no negative effects on puberty progression. However a rat study (https://pubmed.ncbi.nlm.nih.gov/18348701/) showed persistent shorter tibia, reduced cortical bone size, increased chondrocyte apoptosis, and lowered IGF-1. The evidence is too limited and contradictory to recommend over a proper AI. Stick to letrozole or anastrozole.
Part 9 — The Full Protocol Framework
Core (most evidence-backed):HGH: 6–12 IU/day, injected fasted, wait 15–30 min, then fast carbs plus aminosLetrozole: 2.5 mg/dayBerberine: 1000–1500 mg/day with mealsAcarbose: 25–50 mg with carb mealsTUDCA: 500–1000 mg/dayCitrus Bergamot: 500–1500 mg/dayOmega-3: 2–4 g EPA+DHA dailyVitamin D3/K2: 3000–5000 IU D3 plus 100–200 mcg K2 dailyThyroid monitoring (TSH, Free T3, Free T4) — T4 support if neededBlood glucose monitoring — target fasted under 100 mg/dL
Intermediate additions:TYRA-300 (selective FGFR3 inhibitor) — if verifiably pharmaceutical gradeHalotestin 2.5 mg/day — short cycles only, TUDCA mandatoryAbaloparatide — PTHrP signaling, bone density protection from AI useLantus insulin (5–10 IU baseline) — only with full glucose monitoring protocol and safety measures in placeForskolin 20–50 mg/day
Advanced (frontier territory, mostly preclinical data):KY19382 — Wnt/β-catenin reactivation, subcutaneousFOXO4-DRI — senolytic clearance of growth plateSCO-240 — endogenous GH amplificationSOCS2 inhibition — GH signaling amplification
For post-pubescent / closing plates:The aggressive multi-compound stack has diminishing returns once plates are fused. Focus shifts to: maximizing remaining open plates (clavicle, vertebral apophyses), spinal decompression, posture correction. KY19382 and abaloparatide may still be relevant for residual growth centers. Bone density protection becomes more important than growth velocity at this stage.
Part 10 — Bloodwork: Non-Negotiable
Get baseline before starting anything. Repeat at 6 weeks on cycle, then every 2–3 months.
What to check:IGF-1 — confirms GH is working and not bunk, tracks your responseEstradiol (E2) — confirms AI is working, avoid crashing below 5 pg/mLTotal + Free Testosterone — track suppression from AAS if applicableLH / FSH — track HPTA suppressionTSH, Free T3, Free T4 — thyroid health, essential on GHFasting glucose + HbA1c — metabolic health, GH insulin resistanceLipid panel (LDL, HDL, triglycerides) — AI will worsen this, monitorLiver enzymes (ALT, AST) — essential if running any oral AASBone age X-ray — every 4–6 months to track skeletal maturation vs growth velocity
If you are not monitoring bloodwork you are flying blind and have no idea if what you are doing is helping or destroying you.
Part 11 — Risks: Read This Before You Do Anything
This needs to be said clearly and seriously.
You are intervening in the most complex hormonal system in the human body during what may be its most sensitive developmental window. Most of these compounds have no safety data in healthy adolescents. The clinical data that exists is in children with diagnosed growth disorders under close medical supervision with regular monitoring.
Specific serious risks permanent endocrine disruption from AAS/AI misuse — HPTA suppression, infertility, hormonal dysregulation that does not fully recoverBone density loss from chronic E2 suppression — growing taller with structurally weaker bonesOrgan hypertrophy from excessive long-term GH — heart, kidneys, intestinesScoliosis and spinal deformity from aggressive FGFR inhibitionHepatotoxicity from oral AAS — Halotestin is seriously liver toxic, do not run it long termHypoglycemia from insulin — can cause seizures, brain damage, deathCancer risk from Wnt pathway agonists and Hedgehog activators — theoretical but real pathwaysUsing unverified gray market compounds that may be entirely bunk or contaminated with unknown substancesPsychological dependence on external hormonal manipulationBrain development effects from E2 suppression in adolescence — genuinely underresearched
The honest reality: There are no guarantees. You can take everything on this list perfectly and get zero height, or get sides with no growth. How your body responds is heavily genetic. No verified hyper-responder exists in the community. Someone who follows this thread may get 6 cm of extra height. Someone else might get organ issues and nothing else.
If you are a minor considering any of this: at minimum do this with regular bloodwork and ideally with a doctor who understands the compounds involved.
Sources
AI + GH Clinical:https://pubmed.ncbi.nlm.nih.gov/277...om/doi/abs/10.1111/j.1651-2227.1963.tb03805.x
Estrogen and Fusion:https://www.nature.com/articles/pr19992810
CXXC5 / KY19382 / Wnt:https://pmc.ncbi.nlm.nih.gov/articl...tionhttps://pubmed.ncbi.nlm.nih.gov/30971423/
FGFR Inhibitors:https://investor.bridgebio.com/news...://pmc.ncbi.nlm.nih.gov/articles/PMC12668719/
PTHrP / Abaloparatide / Vosoritide:https://www.nejm.org/doi/full/10.1056/NEJMoa1813446
AAS:https://www.jpeds.com/article/S0022...3523/https://pubmed.ncbi.nlm.nih.gov/8464656/
Tamoxifen:https://pubmed.ncbi.nlm.nih.gov/16322179/https://pubmed.ncbi.nlm.nih.gov/18348701/
SOCS2:https://www.nature.com/articles/350...blication/linked-with-missense-mutation-SOCS2
SAG21k:https://pmc.ncbi.nlm.nih.gov/articles/PMC10506518/
SCO-240:https://pubmed.ncbi.nlm.nih.gov/38549435/
This thread is for educational purposes only. Nothing here is medical advice. Everything discussed carries real risks. Do your research, get bloodwork, and if possible work with a doctor who understands what you are doing.
TAGS:
@Zagro,@Menas,@Chad ,@Typhon , @Orka rate the thread
@FutureSlayer can u take away my 90% warning high effort post
monthly costs of 12iu 5 days on and 2 days of is around 260 dollars if u find the right source thats pretty cheap if u have a job
big shout out to Choh Hao li for Hgh
Heightmaxing Guide 101
Thread song:
ive been studying this topic since i learned about it and i have ordered my stack and everything is ready enough about that though tho. In this thread I will go through a couple of things like growth plates, HGH, AIs, AAS, FGFR inhibitors, and more. Some of the topics I will talk about are pretty new knowledge so don't bash on me if I am wrong cuz I'm trying my best
This thread is for educational and harm reduction purposes only. Everything discussed here carries real medical risks. I am not a doctor. Do your own research and consult a professional before touching any of this.
Part 1 — Growth Plates: The Foundation
Before you understand any protocol you need to understand what we are actually working with.
Growth plates (epiphyseal plates) are made of hyaline cartilage and sit between the epiphysis and metaphysis of your long bones. They are divided into three functional zones:
Resting Zone — sits at the top near the end of the bone. Cells here are mostly dormant and act as a reserve supply of chondrocytes, slowly feeding the zones below when needed.
Proliferative Zone — the active factory. Chondrocytes divide rapidly and stack into neat columns. Every division adds a small increment of bone length. This is where the majority of height gain actually happens.
Hypertrophic Zone — cells stop dividing and enlarge significantly. They mineralize the surrounding cartilage matrix and then undergo programmed death, with the hardened cartilage replaced by real bone. Last step before permanent ossification.
When all three zones stop functioning and fully ossify — growth is permanently over.
Key things most people get wrong:
Bone age is not the same as chronological age. A 16 year old with a bone age of 18 has almost no runway left. A 16 year old with a bone age of 13 has potentially years ahead of him. Getting a bone age X-ray is step one before any protocol, period.
Estrogen closes plates, not testosterone directly. Testosterone must convert to estrogen via aromatase to trigger epiphyseal fusion. Men with aromatase deficiency keep growing into their 30s. This single fact is the entire biological rationale for aromatase inhibitors in height protocols.
CXXC5 drives growth plate senescence. As puberty progresses a protein called CXXC5 gradually accumulates in the growth plate. It acts as a negative regulator of Wnt/β-catenin signaling — a biological stop-growing signal that builds up over time. Mice without CXXC5 showed delayed plate senescence and measurable tibial elongation (Choi et al., 2019). Estrogen directly upregulates CXXC5 via estrogen receptor alpha, which connects the AI strategy directly to this molecular mechanism.
The last plates to fuse are typically the clavicle and vertebral ring apophyses, which is why some people keep growing into their early 20s. There is often more runway than assumed.
Part 2 — HGH: The Gas Pedal
HGH is the primary driver of longitudinal bone growth but does not act alone.
The mechanism: GH stimulates the liver to produce IGF-1, IGF-1 binds receptors at the growth plate, chondrocyte proliferation and hypertrophy follows, and longitudinal growth occurs. GH also has direct local effects at the plate itself but IGF-1 is the dominant downstream signal.
Why dose matters: Clinical protocols for idiopathic short stature use roughly 0.3–0.5 mg/kg/week (1–3 IU/day). Higher doses elevate IGF-1 further but receptor saturation creates diminishing returns. People with gigantism who chronically overproduce GH do not appear to hit a hard cap on growth velocity, suggesting that in the right hormonal environment higher doses remain meaningful.
Dosing tiers:4–6 IU/day — solid starting point, meaningful IGF-1 elevation, manageable sides6–8 IU/day — more aggressive, noticeable water retention and joint effects begin12 IU/day — high end, significant side effect risk, requires full support protocol25+ IU/day — extreme territory, meaningful organ growth and metabolic risk, but for purely height u shouldnt be under 10+ ius and if u worried about getting uncanny dont worry u would need to be on 15+ iu for 10 years to become uncanny
HGH Timing (critical and often ignored):Inject on a completely empty stomach. Wait 15–30 minutes, then consume fast acting carbs and amino acids. This maximizes the GH pulse and IGF-1 response. Injecting after food — especially carbs — blunts the effect significantly because elevated insulin at time of injection competes with GH signaling. Morning fasted injection is the most common approach.
Thyroid drain — one of the most overlooked sides:HGH accelerates the conversion of T4 (inactive thyroid hormone) to T3 (active thyroid hormone). Over time this overworks the thyroid and can slow it down, producing symptoms like fatigue, feeling cold, poor recovery, brain fog, and weight gain despite eating normally. This is why thyroid function (TSH, Free T3, Free T4) should be included in all bloodwork panels on cycle. Some users add T4 supplementation proactively as support, especially at higher GH doses.
HGH side effects to monitor:Water retention and bloating (aldosterone/sodium retention)Joint pain and carpal tunnel (fluid pressure on median nerve)Insulin resistance (GH is anti-insulin by nature)Thyroid suppression at sustained high dosesOrgan growth (gut, kidneys, heart) at very high long term dosesAcromegalic features (jaw, brow, hands, feet) — takes years at high doses but irreversible
Pros:Muscle growth and improved body composition via IGF-1Fat loss through lipolysisFaster recoveryImproved skin collagen and elasticityStronger bones via increased bone mineral densityLongitudinal growth if plates are openBetter sleep quality
Part 3 — Support Supplements: Non-Negotiable
This section is essential and most people skip it. Every compound in this thread creates metabolic stress somewhere. These supplements directly counter the most common and serious side effects.
Berberine (1000–1500 mg/day, split into 2–3 doses with meals)HGH causes insulin resistance. Berberine activates AMPK (the same pathway as metformin) and directly improves insulin sensitivity. This is the most important metabolic support compound on a GH cycle. It also improves lipid profiles, reduces LDL, and has mild anti-inflammatory effects. Take with meals to avoid GI upset. Risks: GI discomfort at high doses, mild hypoglycemia if stacked aggressively with other insulin sensitizers. Do not stack with metformin without monitoring.
Acarbose (25–50 mg with carb-containing meals)Alpha-glucosidase inhibitor. Slows the digestion and absorption of carbohydrates, which blunts post-meal blood glucose spikes that GH exaggerates. Particularly useful around your post-injection carb intake. Works at the gut level so systemic side effects are minimal, but expect significant gas and bloating when you first start — this fades over 2–3 weeks as gut bacteria adapt. Risk: GI discomfort, do not use during hypoglycemic episodes as it blocks carb absorption and will prevent glucose recovery.
T4/Thyroid Support (dosing varies — get bloodwork first)As explained above, HGH drains the thyroid over time by accelerating T4 to T3 conversion. If bloodwork shows TSH rising or Free T3/T4 falling, low dose T4 supplementation (levothyroxine, 25–50 mcg/day is a common starting point) can restore balance. Do not start thyroid hormones without baseline bloodwork — supplementing when your thyroid is functioning normally can suppress natural production. Risks: palpitations, anxiety, insomnia, hyperthyroidism at excessive doses, permanent suppression of natural thyroid function if run too aggressively long term.
TUDCA (500–1000 mg/day)Tauroursodeoxycholic acid — a bile acid that directly protects liver cells from stress and apoptosis. Essential if you are running any oral AAS (Halotestin is significantly hepatotoxic). Reduces liver enzyme elevation, protects against cholestasis. Very well tolerated. Risks: mild GI effects at high doses, otherwise considered very safe.
Citrus Bergamot (500–1500 mg/day)Crashed E2 from AIs destroys your lipid profile — HDL drops, LDL rises, cardiovascular risk climbs. Citrus bergamot is one of the most evidence-backed natural compounds for improving cholesterol. It reduces LDL, raises HDL, and reduces triglycerides. Consider it mandatory if you are running an AI. Risks: very low, mild GI upset in some people.
Cod Liver Oil / Omega-3 (2–4 g EPA+DHA daily)Reduces systemic inflammation, supports cardiovascular health, improves lipid profile synergistically with bergamot, and protects joints which GH can stress via fluid retention and cartilage effects. Get a high quality molecularly distilled product to avoid heavy metal contamination. Risks: fishy burps, mild blood thinning at very high doses, avoid mega-dosing before surgery.
Vitamin D3 + K2Both are essential for bone mineralization. If you are growing bone you need adequate D3 (2000–5000 IU/day) paired with K2 (MK-7, 100–200 mcg/day) to direct calcium into bone rather than soft tissue. Deficiency in either will blunt the skeletal gains from your protocol.
Zinc (25–50 mg/day with food)Supports testosterone production, immune function, and IGF-1 signaling. Commonly depleted during intense training and hormonal manipulation. Take with food to avoid nausea. Do not exceed 50 mg/day long term without copper supplementation as zinc depletes copper.
Part 4 — Blood Glucose Management and Insulin
Why blood glucose matters on GH:GH is inherently anti-insulin — it raises blood glucose by suppressing peripheral glucose uptake. At high doses this becomes significant and unmanaged insulin resistance leads to chronic elevated blood sugar, which causes long term metabolic damage and paradoxically blunts IGF-1 signaling efficiency.
Blood glucose monitoring protocol:Get a cheap glucometer. Check fasted morning glucose and post-meal glucose. Target fasted BG under 100 mg/dL, post-meal under 140 mg/dL at 2 hours. If numbers are creeping up, increase berberine dose and add acarbose before carb meals.
The 10–15g carbs per IU rule:After injecting GH fasted and waiting 15–30 minutes, consume 10–15 grams of fast acting carbs per IU of GH to keep blood sugar stable and avoid hypoglycemia rebound. Pair with amino acids to maximize the IGF-1 anabolic window.
Lantus Insulin (long-acting, for advanced users only):Lantus (insulin glargine) is a 24-hour basal insulin. It is used in advanced stacks because insulin and IGF-1 are synergistic — insulin drives glucose and amino acids into cells creating a highly anabolic environment that multiplies the effect of elevated IGF-1 from GH. In the context of height, this means more fuel delivered to chondrocytes at exactly the time GH is signaling them to proliferate.
Typical starting dose: 5–10 IU subcutaneous, once daily, usually at night. Titrate slowly based on fasted morning glucose. Target fasted BG of 80–90 mg/dL.
This is genuinely dangerous. Read this carefully:Insulin overdose causes hypoglycemia which can cause seizures, brain damage, and death within minutes. Always have fast acting glucose (dextrose tablets, juice, regular soda) immediately accessible before every injection. Never inject Lantus and then go to sleep without someone who knows what you are doing nearby. Never use rapid acting insulin (Humalog, Novorapid) unless you have extensive experience — the margin for error is extremely small. Symptoms of hypoglycemia: shakiness, sweating, confusion, heart racing, vision changes. Treat immediately with 15–20g fast acting glucose and recheck in 15 minutes. Do not use insulin if you are not monitoring blood glucose regularly. Do not use insulin if you are alone, especially not at night.
Risks of long term insulin use: insulin resistance, weight gain, hypoglycemic episodes, dependency, lipodystrophy at injection sites.
This is the highest risk compound in any heightmaxxing stack. The potential synergy with GH/IGF-1 is real, but it should only be considered by those who fully understand glucose management and have all safety measures in place.
Part 5 — AIs (Aromatase Inhibitors): Stopping the Clock
The most clinically validated intervention in this entire thread alongside GH.
The biology: Aromatase converts testosterone to estrogen. Estrogen upregulates CXXC5, suppresses Wnt/β-catenin, and drives growth plate senescence and fusion. Block aromatase, keep E2 low, and the senescence clock slows dramatically.
A 2016 RCT (https://pubmed.ncbi.nlm.nih.gov/27710241/) and a 2025 meta-analysis (https://pmc.ncbi.nlm.nih.gov/articles/PMC12342369/) both confirmed that combining AIs with GH produces significantly greater adult height outcomes than GH alone in pubertal boys with idiopathic short stature. This is the most evidence-backed combination in heightmaxxing.
Letrozole (2.5 mg/day) — gold standard, most potent non-steroidal reversible AI. Crushes E2 to 5–15 pg/mL range. Most clinical height studies use this dose.
Anastrozole (0.5–1 mg/day) — weaker than letrozole but has more pediatric ISS trial data. Less aggressive suppression, which some argue is safer for bone density preservation.
Fulvestrant (Faslodex) — SERD, degrades estrogen receptors entirely rather than just blocking aromatase. Nuclear option. The ICI 182,780 mouse study (https://www.nature.com/articles/pr19992810) showed it can prevent estrogen-accelerated bone maturation even when E2 is present. Used in advanced protocols stacked with an AI for dual pathway blockade.
Exemestane (Aromasin, 12.5–25 mg EOD) — steroidal suicidal AI, permanently destroys aromatase molecules. Has a steroidal backbone which can behave differently from non-steroidal AIs. Some rat data showed reduced bone length. Controversial in this context — most community consensus leans toward letrozole.
Critical risks:Bone density loss — E2 is essential for bone mineralization. Chronic suppression while growing taller means potentially weaker bones. Counteract with Vitamin D3/K2, calcium, and Abaloparatide if running aggressive suppression. Lipid dysregulation — E2 is cardioprotective. Crashed E2 worsens cholesterol profile significantly. Run citrus bergamot and omega-3 mandatory. Joint pain, mood issues, libido loss. Potential neurological effects in adolescents — E2 plays a role in brain development during puberty. This is underresearched and a genuine unknown risk. Get bloodwork every 6–8 weeks minimum.
Part 6 — FGFR Inhibitors: Removing the Brake
FGFR3 is a negative regulator of bone growth — a biological brake signal in the growth plate. Blocking it allows the GH/IGF-1 gas pedal to work without interference.
The framework: HGH provides the raw IGF-1 anabolic signal (gas). FGFR3 inhibition removes the stop-growth signal (brake removal). Together: unimpeded growth velocity.
Infigratinib — oral FGFR1-3 inhibitor. RCT data in achondroplasia kids showed +1.74–2.50 cm/year extra annualized height velocity vs placebo (https://investor.bridgebio.com/news...roportionality-in-Achondroplasia/default.aspx). First drug to show statistically significant improvement in body proportionality in ACH. The problem: hitting FGFR1 and FGFR2 causes hyperphosphatemia and additional off-target toxicity. More studied than TYRA-300 but riskier.
TYRA-300 (Dabogratinib) — selective FGFR3 only inhibitor. First-in-class. Mouse data (https://insight.jci.org/articles/view/189307) showed significant increases in femur length (+3.7–5%), tibia length (+3.75–6%), and improved skeletal proportionality even in wild-type (normal) mice — not just ACH models. This is huge because it suggests benefit even without a pathological FGFR3 mutation. Spares FGFR1/2/4 so avoids the phosphate toxicity of infigratinib. Main issues: no human height trial data yet, very difficult to verify product purity from gray market sources, expensive.
Erdafitinib — pan-FGFR1-4 inhibitor, most potent but least selective. One case study showed extreme height velocity in a child on it for cancer treatment but also caused rapid overgrowth, kyphoscoliosis, and spinal deformities (https://www.sciencedirect.com/science/article/pii/S2405844024069184). Mechanism is proven but risk profile is the worst of the group. Not recommended.
Loxo-435 — highly selective FGFR3 inhibitor from Lilly. Promising alongside TYRA-300 but even less data available.
Vosoritide — CNP analog, works downstream of FGFR3 by raising cGMP and inhibiting the MAPK/ERK pathway rather than blocking the receptor directly. FDA approved for achondroplasia. RCT (https://www.nejm.org/doi/full/10.1056/NEJMoa1813446) showed +1.57 cm/year extra growth velocity vs placebo. Safer mechanism but weaker effect than direct FGFR3 blockade and degrades very fast requiring careful storage and daily injection. Expensive.
Honest reality check: Most FGFR compounds on the gray market are unverifiable. There are essentially no reputable lab tests confirming that what is sold as TYRA-300 or infigratinib actually contains what is claimed. For most people optimizing GH + letrozole will outperform spending money on potentially bunk FGFR compounds. TYRA-300 is worth pursuing only if you can verify pharmaceutical grade product.
Part 7 — AAS: The Double-Edged Sword
Complicated territory. AAS can both help and hurt height depending on what you use and when.
The problem with most AAS: When any androgen enters the bloodstream it reaches growth plate chondrocytes and binds directly to androgen receptors. These receptors accelerate terminal differentiation — telling chondrocytes to stop dividing and mature into bone faster. This happens regardless of dose. There is no low enough dose that completely avoids this effect. Aromatizable androgens compound this by also converting to estrogen, advancing bone age rapidly.
Halotestin (Fluoxymesterone) @ 2.5 mg/day — the most defensible option:Non-aromatizing. Cannot convert to estrogen. Provides direct AR stimulus at the growth plate, upregulating local IGF-1 receptor expression and making chondrocytes hypersensitive to the GH signal. Provides a pubertal growth stimulus without triggering the estrogen-mediated fusion pathway. The 1993 Moore study (https://pubmed.ncbi.nlm.nih.gov/8464656/) showed low-dose Halotestin in boys with growth delays resulted in final height +6.1 cm above predicted genetic baseline, with bone age advancing less than growth velocity. Keep cycles short — Halotestin is significantly hepatotoxic. Run TUDCA mandatory. Do not exceed 2.5 mg/day for height purposes.
Anavar (Oxandrolone) @ 2.5–5 mg/day:Mildest of the three. Has some pediatric ISS data. Low aromatization rate and reduces aromatizable substrate via negative feedback on HPTA. One study (https://www.jpeds.com/article/S0022-3476(71)80204-4/fulltext) showed increased height velocity but also accelerated skeletal age — some children in the trial lost 1.5–7.5 cm of predicted adult height. The velocity increase may not translate to better final height. More evidence than Halotestin but less favorable risk/reward for pure height purposes.
Winstrol (Stanozolol):Animal data (https://pubmed.ncbi.nlm.nih.gov/21823523/) shows direct effects on growth plate chondrocytes via estrogen receptor pathways. Less data than the other two. Not a first choice for height.
Masteron, Primobolan: Non-aromatizing, mild. Less data for height specifically but lower risk profile than Halotestin. May be useful for androgenic stimulus with lower hepatotoxicity.
Bottom line: If you use any AAS on a height protocol use the lowest effective dose of a non-aromatizing compound and stack mandatorily with an AI. Never use testosterone or aromatizable androgens without an AI. Monitor bone age every 4–6 months. The younger you are the more conservative you need to be.
Part 8 — Advanced Compounds
KY19382 — Wnt/β-catenin Reactivation:Small molecule CXXC5-DVL inhibitor. By disrupting the CXXC5-Dvl interaction it stabilizes nuclear β-catenin and reactivates Wnt signaling in the growth plate — directly reversing the senescence mechanism. Mouse data (https://pmc.ncbi.nlm.nih.gov/articles/PMC6458850/): 0.1 mg/kg daily for 10 weeks produced statistically significant tibial elongation (p<0.0005), increased proliferating chondrocytes, expanded proliferative and hypertrophic zones. Also promotes facial bone remodeling via periosteal apposition. Administration: subcutaneous injection preferred over transdermal. Caveats: all data is preclinical (mouse/cell line), no human height trials, Wnt pathway activation warrants cancer monitoring (though in cancer cell lines KY19382 showed anti-tumor effects via CDK1 suppression suggesting context-dependent behavior).
FOXO4-DRI — Senolytic Clearance:Synthetic peptide that selectively eliminates senescent cells by disrupting the FOXO4-p53 protective interaction, triggering apoptosis specifically in senescent chondrocytes. Rationale: senescent chondrocytes secrete SASP inflammatory factors (IL-6, MMPs) that create a toxic microenvironment suppressing nearby healthy chondrocytes and depleting the resting zone stem cell pool. Clearing them reduces this inflammatory burden and allows the remaining healthy chondrocytes to proliferate more freely. Highly theoretical for height in humans. No human data. Interesting mechanism but not something most people should approach casually.
SAG21k / Purmorphamine — Hedgehog Pathway:Small molecules that directly activate Smoothened (SMO) in the Hedgehog signaling pathway, bypassing normal Patched inhibition and activating Gli transcription factors. Effect: more epiphyseal stem cells multiply, chondrocyte columns thicken, growth plates become more active. Mouse data (https://pmc.ncbi.nlm.nih.gov/articles/PMC10506518/) showed strong enhancement of chondrogenesis. Major concern: Hedgehog pathway overactivation is strongly linked to cancer development. This is not a minor theoretical risk — sustained Hh pathway activation is a known driver of multiple cancer types. Only worth considering in very strategic short term windows if at all.
SOCS2 Inhibition:SOCS2 is a negative feedback regulator of GH signaling. It binds the phosphorylated GH receptor, promotes its degradation, and dampens STAT5 activation and IGF-1 production. Inhibiting SOCS2 removes this brake on GH signaling itself — essentially amplifying exogenous GH. Mice without SOCS2 grew 30–40% larger than wild-type with increased long-bone length (https://www.nature.com/articles/35016611). A human SOCS2 mutation was linked to gigantism. Risks: chronic GH/IGF-1 hypersignaling causes insulin resistance, potential organ enlargement, and IGF-1 is mitogenic meaning cancer risk with chronic elevation.
SCO-240 — Endogenous GH Amplification:Oral SSTR5 antagonist. Somatostatin normally inhibits GH release by binding SSTR5 on pituitary somatotrophs. SCO-240 blocks this, allowing the pituitary to release more GH in a physiological pulsatile pattern without affecting other pituitary hormones. Phase 1 data (https://pubmed.ncbi.nlm.nih.gov/38549435/) showed robust dose-dependent GH secretion comparable to therapeutic rhGH levels. Advantage over injected GH: mimics natural pulsatile pattern more closely. Disadvantages: only Phase 1 adult data, no height efficacy data in children yet, still carries standard GH excess risks.
Abaloparatide / Teriparatide — PTHrP Analogs:Both bind PTH1R, mimicking the natural PTHrP signal that keeps chondrocytes in the proliferative state and delays hypertrophic transition. Intermittent daily dosing expands proliferative and hypertrophic zones, increases chondrocyte columns, and prolongs the active growth window before senescence. Abaloparatide more closely mimics PTHrP's natural growth plate role, potentially providing a cleaner anabolic effect with less calcium/resorption side effects than teriparatide. Abalo also counteracts the bone density loss caused by aggressive AI use — making it arguably mandatory at the advanced level. Main risk: rat studies at high doses showed osteosarcoma signal. Clinical doses appear significantly below the threshold where this was observed but it is a real consideration for long term use.
Epitalon (Telomerase Activator):Aims to reduce the biological age of chondrocytes by activating telomerase and slowing cellular senescence. Highly speculative for height. The concept of keeping chondrocytes biologically younger for longer is mechanistically sound but human height data does not exist. Low risk profile. Subcutaneous injection.
Forskolin (20–50 mg/day)directly activates adenylyl cyclase, increases intracellular cAMP, and amplifies the mitogenic effects of IGF-1 and GH within chondrocytes. Makes the growth signal hit harder at the cellular level. Relatively accessible, low risk compared to everything else here. GI upset possible at higher doses.
Tamoxifen:SERM — selectively blocks estrogen receptors in some tissues. One study (https://pubmed.ncbi.nlm.nih.gov/16322179/) in 7 short pubertal boys showed tamoxifen significantly slowed skeletal maturation and increased predicted adult height by around 4 inches with no negative effects on puberty progression. However a rat study (https://pubmed.ncbi.nlm.nih.gov/18348701/) showed persistent shorter tibia, reduced cortical bone size, increased chondrocyte apoptosis, and lowered IGF-1. The evidence is too limited and contradictory to recommend over a proper AI. Stick to letrozole or anastrozole.
Part 9 — The Full Protocol Framework
Core (most evidence-backed):HGH: 6–12 IU/day, injected fasted, wait 15–30 min, then fast carbs plus aminosLetrozole: 2.5 mg/dayBerberine: 1000–1500 mg/day with mealsAcarbose: 25–50 mg with carb mealsTUDCA: 500–1000 mg/dayCitrus Bergamot: 500–1500 mg/dayOmega-3: 2–4 g EPA+DHA dailyVitamin D3/K2: 3000–5000 IU D3 plus 100–200 mcg K2 dailyThyroid monitoring (TSH, Free T3, Free T4) — T4 support if neededBlood glucose monitoring — target fasted under 100 mg/dL
Intermediate additions:TYRA-300 (selective FGFR3 inhibitor) — if verifiably pharmaceutical gradeHalotestin 2.5 mg/day — short cycles only, TUDCA mandatoryAbaloparatide — PTHrP signaling, bone density protection from AI useLantus insulin (5–10 IU baseline) — only with full glucose monitoring protocol and safety measures in placeForskolin 20–50 mg/day
Advanced (frontier territory, mostly preclinical data):KY19382 — Wnt/β-catenin reactivation, subcutaneousFOXO4-DRI — senolytic clearance of growth plateSCO-240 — endogenous GH amplificationSOCS2 inhibition — GH signaling amplification
For post-pubescent / closing plates:The aggressive multi-compound stack has diminishing returns once plates are fused. Focus shifts to: maximizing remaining open plates (clavicle, vertebral apophyses), spinal decompression, posture correction. KY19382 and abaloparatide may still be relevant for residual growth centers. Bone density protection becomes more important than growth velocity at this stage.
Part 10 — Bloodwork: Non-Negotiable
Get baseline before starting anything. Repeat at 6 weeks on cycle, then every 2–3 months.
What to check:IGF-1 — confirms GH is working and not bunk, tracks your responseEstradiol (E2) — confirms AI is working, avoid crashing below 5 pg/mLTotal + Free Testosterone — track suppression from AAS if applicableLH / FSH — track HPTA suppressionTSH, Free T3, Free T4 — thyroid health, essential on GHFasting glucose + HbA1c — metabolic health, GH insulin resistanceLipid panel (LDL, HDL, triglycerides) — AI will worsen this, monitorLiver enzymes (ALT, AST) — essential if running any oral AASBone age X-ray — every 4–6 months to track skeletal maturation vs growth velocity
If you are not monitoring bloodwork you are flying blind and have no idea if what you are doing is helping or destroying you.
Part 11 — Risks: Read This Before You Do Anything
This needs to be said clearly and seriously.
You are intervening in the most complex hormonal system in the human body during what may be its most sensitive developmental window. Most of these compounds have no safety data in healthy adolescents. The clinical data that exists is in children with diagnosed growth disorders under close medical supervision with regular monitoring.
Specific serious risks permanent endocrine disruption from AAS/AI misuse — HPTA suppression, infertility, hormonal dysregulation that does not fully recoverBone density loss from chronic E2 suppression — growing taller with structurally weaker bonesOrgan hypertrophy from excessive long-term GH — heart, kidneys, intestinesScoliosis and spinal deformity from aggressive FGFR inhibitionHepatotoxicity from oral AAS — Halotestin is seriously liver toxic, do not run it long termHypoglycemia from insulin — can cause seizures, brain damage, deathCancer risk from Wnt pathway agonists and Hedgehog activators — theoretical but real pathwaysUsing unverified gray market compounds that may be entirely bunk or contaminated with unknown substancesPsychological dependence on external hormonal manipulationBrain development effects from E2 suppression in adolescence — genuinely underresearched
The honest reality: There are no guarantees. You can take everything on this list perfectly and get zero height, or get sides with no growth. How your body responds is heavily genetic. No verified hyper-responder exists in the community. Someone who follows this thread may get 6 cm of extra height. Someone else might get organ issues and nothing else.
If you are a minor considering any of this: at minimum do this with regular bloodwork and ideally with a doctor who understands the compounds involved.
Sources
AI + GH Clinical:https://pubmed.ncbi.nlm.nih.gov/277...om/doi/abs/10.1111/j.1651-2227.1963.tb03805.x
Estrogen and Fusion:https://www.nature.com/articles/pr19992810
CXXC5 / KY19382 / Wnt:https://pmc.ncbi.nlm.nih.gov/articl...tionhttps://pubmed.ncbi.nlm.nih.gov/30971423/
FGFR Inhibitors:https://investor.bridgebio.com/news...://pmc.ncbi.nlm.nih.gov/articles/PMC12668719/
PTHrP / Abaloparatide / Vosoritide:https://www.nejm.org/doi/full/10.1056/NEJMoa1813446
AAS:https://www.jpeds.com/article/S0022...3523/https://pubmed.ncbi.nlm.nih.gov/8464656/
Tamoxifen:https://pubmed.ncbi.nlm.nih.gov/16322179/https://pubmed.ncbi.nlm.nih.gov/18348701/
SOCS2:https://www.nature.com/articles/350...blication/linked-with-missense-mutation-SOCS2
SAG21k:https://pmc.ncbi.nlm.nih.gov/articles/PMC10506518/
SCO-240:https://pubmed.ncbi.nlm.nih.gov/38549435/
This thread is for educational purposes only. Nothing here is medical advice. Everything discussed carries real risks. Do your research, get bloodwork, and if possible work with a doctor who understands what you are doing.
TAGS:
@Zagro,@Menas,@Chad ,@Typhon , @Orka rate the thread
@FutureSlayer can u take away my 90% warning high effort post
monthly costs of 12iu 5 days on and 2 days of is around 260 dollars if u find the right source thats pretty cheap if u have a job
big shout out to Choh Hao li for Hgh
knowledge is mine nigger
jfl none of the threads u see are actuall info ur just a retarded bitch that cant learn jack shit
Heightmaxing Guide 101
Thread song:
ive been studying this topic since i learned about it and i have ordered my stack and everything is ready enough about that though tho. In this thread I will go through a couple of things like growth plates, HGH, AIs, AAS, FGFR inhibitors, and more. Some of the topics I will talk about are pretty new knowledge so don't bash on me if I am wrong cuz I'm trying my best
This thread is for educational and harm reduction purposes only. Everything discussed here carries real medical risks. I am not a doctor. Do your own research and consult a professional before touching any of this.
Part 1 — Growth Plates: The Foundation
Before you understand any protocol you need to understand what we are actually working with.
Growth plates (epiphyseal plates) are made of hyaline cartilage and sit between the epiphysis and metaphysis of your long bones. They are divided into three functional zones:
Resting Zone — sits at the top near the end of the bone. Cells here are mostly dormant and act as a reserve supply of chondrocytes, slowly feeding the zones below when needed.
Proliferative Zone — the active factory. Chondrocytes divide rapidly and stack into neat columns. Every division adds a small increment of bone length. This is where the majority of height gain actually happens.
Hypertrophic Zone — cells stop dividing and enlarge significantly. They mineralize the surrounding cartilage matrix and then undergo programmed death, with the hardened cartilage replaced by real bone. Last step before permanent ossification.
When all three zones stop functioning and fully ossify — growth is permanently over.
Key things most people get wrong:
Bone age is not the same as chronological age. A 16 year old with a bone age of 18 has almost no runway left. A 16 year old with a bone age of 13 has potentially years ahead of him. Getting a bone age X-ray is step one before any protocol, period.
Estrogen closes plates, not testosterone directly. Testosterone must convert to estrogen via aromatase to trigger epiphyseal fusion. Men with aromatase deficiency keep growing into their 30s. This single fact is the entire biological rationale for aromatase inhibitors in height protocols.
CXXC5 drives growth plate senescence. As puberty progresses a protein called CXXC5 gradually accumulates in the growth plate. It acts as a negative regulator of Wnt/β-catenin signaling — a biological stop-growing signal that builds up over time. Mice without CXXC5 showed delayed plate senescence and measurable tibial elongation (Choi et al., 2019). Estrogen directly upregulates CXXC5 via estrogen receptor alpha, which connects the AI strategy directly to this molecular mechanism.
The last plates to fuse are typically the clavicle and vertebral ring apophyses, which is why some people keep growing into their early 20s. There is often more runway than assumed.
Part 2 — HGH: The Gas Pedal
HGH is the primary driver of longitudinal bone growth but does not act alone.
The mechanism: GH stimulates the liver to produce IGF-1, IGF-1 binds receptors at the growth plate, chondrocyte proliferation and hypertrophy follows, and longitudinal growth occurs. GH also has direct local effects at the plate itself but IGF-1 is the dominant downstream signal.
Why dose matters: Clinical protocols for idiopathic short stature use roughly 0.3–0.5 mg/kg/week (1–3 IU/day). Higher doses elevate IGF-1 further but receptor saturation creates diminishing returns. People with gigantism who chronically overproduce GH do not appear to hit a hard cap on growth velocity, suggesting that in the right hormonal environment higher doses remain meaningful.
Dosing tiers:4–6 IU/day — solid starting point, meaningful IGF-1 elevation, manageable sides6–8 IU/day — more aggressive, noticeable water retention and joint effects begin12 IU/day — high end, significant side effect risk, requires full support protocol25+ IU/day — extreme territory, meaningful organ growth and metabolic risk, but for purely height u shouldnt be under 10+ ius and if u worried about getting uncanny dont worry u would need to be on 15+ iu for 10 years to become uncanny
HGH Timing (critical and often ignored):Inject on a completely empty stomach. Wait 15–30 minutes, then consume fast acting carbs and amino acids. This maximizes the GH pulse and IGF-1 response. Injecting after food — especially carbs — blunts the effect significantly because elevated insulin at time of injection competes with GH signaling. Morning fasted injection is the most common approach.
Thyroid drain — one of the most overlooked sides:HGH accelerates the conversion of T4 (inactive thyroid hormone) to T3 (active thyroid hormone). Over time this overworks the thyroid and can slow it down, producing symptoms like fatigue, feeling cold, poor recovery, brain fog, and weight gain despite eating normally. This is why thyroid function (TSH, Free T3, Free T4) should be included in all bloodwork panels on cycle. Some users add T4 supplementation proactively as support, especially at higher GH doses.
HGH side effects to monitor:Water retention and bloating (aldosterone/sodium retention)Joint pain and carpal tunnel (fluid pressure on median nerve)Insulin resistance (GH is anti-insulin by nature)Thyroid suppression at sustained high dosesOrgan growth (gut, kidneys, heart) at very high long term dosesAcromegalic features (jaw, brow, hands, feet) — takes years at high doses but irreversible
Pros:Muscle growth and improved body composition via IGF-1Fat loss through lipolysisFaster recoveryImproved skin collagen and elasticityStronger bones via increased bone mineral densityLongitudinal growth if plates are openBetter sleep quality
Part 3 — Support Supplements: Non-Negotiable
This section is essential and most people skip it. Every compound in this thread creates metabolic stress somewhere. These supplements directly counter the most common and serious side effects.
Berberine (1000–1500 mg/day, split into 2–3 doses with meals)HGH causes insulin resistance. Berberine activates AMPK (the same pathway as metformin) and directly improves insulin sensitivity. This is the most important metabolic support compound on a GH cycle. It also improves lipid profiles, reduces LDL, and has mild anti-inflammatory effects. Take with meals to avoid GI upset. Risks: GI discomfort at high doses, mild hypoglycemia if stacked aggressively with other insulin sensitizers. Do not stack with metformin without monitoring.
Acarbose (25–50 mg with carb-containing meals)Alpha-glucosidase inhibitor. Slows the digestion and absorption of carbohydrates, which blunts post-meal blood glucose spikes that GH exaggerates. Particularly useful around your post-injection carb intake. Works at the gut level so systemic side effects are minimal, but expect significant gas and bloating when you first start — this fades over 2–3 weeks as gut bacteria adapt. Risk: GI discomfort, do not use during hypoglycemic episodes as it blocks carb absorption and will prevent glucose recovery.
T4/Thyroid Support (dosing varies — get bloodwork first)As explained above, HGH drains the thyroid over time by accelerating T4 to T3 conversion. If bloodwork shows TSH rising or Free T3/T4 falling, low dose T4 supplementation (levothyroxine, 25–50 mcg/day is a common starting point) can restore balance. Do not start thyroid hormones without baseline bloodwork — supplementing when your thyroid is functioning normally can suppress natural production. Risks: palpitations, anxiety, insomnia, hyperthyroidism at excessive doses, permanent suppression of natural thyroid function if run too aggressively long term.
TUDCA (500–1000 mg/day)Tauroursodeoxycholic acid — a bile acid that directly protects liver cells from stress and apoptosis. Essential if you are running any oral AAS (Halotestin is significantly hepatotoxic). Reduces liver enzyme elevation, protects against cholestasis. Very well tolerated. Risks: mild GI effects at high doses, otherwise considered very safe.
Citrus Bergamot (500–1500 mg/day)Crashed E2 from AIs destroys your lipid profile — HDL drops, LDL rises, cardiovascular risk climbs. Citrus bergamot is one of the most evidence-backed natural compounds for improving cholesterol. It reduces LDL, raises HDL, and reduces triglycerides. Consider it mandatory if you are running an AI. Risks: very low, mild GI upset in some people.
Cod Liver Oil / Omega-3 (2–4 g EPA+DHA daily)Reduces systemic inflammation, supports cardiovascular health, improves lipid profile synergistically with bergamot, and protects joints which GH can stress via fluid retention and cartilage effects. Get a high quality molecularly distilled product to avoid heavy metal contamination. Risks: fishy burps, mild blood thinning at very high doses, avoid mega-dosing before surgery.
Vitamin D3 + K2Both are essential for bone mineralization. If you are growing bone you need adequate D3 (2000–5000 IU/day) paired with K2 (MK-7, 100–200 mcg/day) to direct calcium into bone rather than soft tissue. Deficiency in either will blunt the skeletal gains from your protocol.
Zinc (25–50 mg/day with food)Supports testosterone production, immune function, and IGF-1 signaling. Commonly depleted during intense training and hormonal manipulation. Take with food to avoid nausea. Do not exceed 50 mg/day long term without copper supplementation as zinc depletes copper.
Part 4 — Blood Glucose Management and Insulin
Why blood glucose matters on GH:GH is inherently anti-insulin — it raises blood glucose by suppressing peripheral glucose uptake. At high doses this becomes significant and unmanaged insulin resistance leads to chronic elevated blood sugar, which causes long term metabolic damage and paradoxically blunts IGF-1 signaling efficiency.
Blood glucose monitoring protocol:Get a cheap glucometer. Check fasted morning glucose and post-meal glucose. Target fasted BG under 100 mg/dL, post-meal under 140 mg/dL at 2 hours. If numbers are creeping up, increase berberine dose and add acarbose before carb meals.
The 10–15g carbs per IU rule:After injecting GH fasted and waiting 15–30 minutes, consume 10–15 grams of fast acting carbs per IU of GH to keep blood sugar stable and avoid hypoglycemia rebound. Pair with amino acids to maximize the IGF-1 anabolic window.
Lantus Insulin (long-acting, for advanced users only):Lantus (insulin glargine) is a 24-hour basal insulin. It is used in advanced stacks because insulin and IGF-1 are synergistic — insulin drives glucose and amino acids into cells creating a highly anabolic environment that multiplies the effect of elevated IGF-1 from GH. In the context of height, this means more fuel delivered to chondrocytes at exactly the time GH is signaling them to proliferate.
Typical starting dose: 5–10 IU subcutaneous, once daily, usually at night. Titrate slowly based on fasted morning glucose. Target fasted BG of 80–90 mg/dL.
This is genuinely dangerous. Read this carefully:Insulin overdose causes hypoglycemia which can cause seizures, brain damage, and death within minutes. Always have fast acting glucose (dextrose tablets, juice, regular soda) immediately accessible before every injection. Never inject Lantus and then go to sleep without someone who knows what you are doing nearby. Never use rapid acting insulin (Humalog, Novorapid) unless you have extensive experience — the margin for error is extremely small. Symptoms of hypoglycemia: shakiness, sweating, confusion, heart racing, vision changes. Treat immediately with 15–20g fast acting glucose and recheck in 15 minutes. Do not use insulin if you are not monitoring blood glucose regularly. Do not use insulin if you are alone, especially not at night.
Risks of long term insulin use: insulin resistance, weight gain, hypoglycemic episodes, dependency, lipodystrophy at injection sites.
This is the highest risk compound in any heightmaxxing stack. The potential synergy with GH/IGF-1 is real, but it should only be considered by those who fully understand glucose management and have all safety measures in place.
Part 5 — AIs (Aromatase Inhibitors): Stopping the Clock
The most clinically validated intervention in this entire thread alongside GH.
The biology: Aromatase converts testosterone to estrogen. Estrogen upregulates CXXC5, suppresses Wnt/β-catenin, and drives growth plate senescence and fusion. Block aromatase, keep E2 low, and the senescence clock slows dramatically.
A 2016 RCT (https://pubmed.ncbi.nlm.nih.gov/27710241/) and a 2025 meta-analysis (https://pmc.ncbi.nlm.nih.gov/articles/PMC12342369/) both confirmed that combining AIs with GH produces significantly greater adult height outcomes than GH alone in pubertal boys with idiopathic short stature. This is the most evidence-backed combination in heightmaxxing.
Letrozole (2.5 mg/day) — gold standard, most potent non-steroidal reversible AI. Crushes E2 to 5–15 pg/mL range. Most clinical height studies use this dose.
Anastrozole (0.5–1 mg/day) — weaker than letrozole but has more pediatric ISS trial data. Less aggressive suppression, which some argue is safer for bone density preservation.
Fulvestrant (Faslodex) — SERD, degrades estrogen receptors entirely rather than just blocking aromatase. Nuclear option. The ICI 182,780 mouse study (https://www.nature.com/articles/pr19992810) showed it can prevent estrogen-accelerated bone maturation even when E2 is present. Used in advanced protocols stacked with an AI for dual pathway blockade.
Exemestane (Aromasin, 12.5–25 mg EOD) — steroidal suicidal AI, permanently destroys aromatase molecules. Has a steroidal backbone which can behave differently from non-steroidal AIs. Some rat data showed reduced bone length. Controversial in this context — most community consensus leans toward letrozole.
Critical risks:Bone density loss — E2 is essential for bone mineralization. Chronic suppression while growing taller means potentially weaker bones. Counteract with Vitamin D3/K2, calcium, and Abaloparatide if running aggressive suppression. Lipid dysregulation — E2 is cardioprotective. Crashed E2 worsens cholesterol profile significantly. Run citrus bergamot and omega-3 mandatory. Joint pain, mood issues, libido loss. Potential neurological effects in adolescents — E2 plays a role in brain development during puberty. This is underresearched and a genuine unknown risk. Get bloodwork every 6–8 weeks minimum.
Part 6 — FGFR Inhibitors: Removing the Brake
FGFR3 is a negative regulator of bone growth — a biological brake signal in the growth plate. Blocking it allows the GH/IGF-1 gas pedal to work without interference.
The framework: HGH provides the raw IGF-1 anabolic signal (gas). FGFR3 inhibition removes the stop-growth signal (brake removal). Together: unimpeded growth velocity.
Infigratinib — oral FGFR1-3 inhibitor. RCT data in achondroplasia kids showed +1.74–2.50 cm/year extra annualized height velocity vs placebo (https://investor.bridgebio.com/news...roportionality-in-Achondroplasia/default.aspx). First drug to show statistically significant improvement in body proportionality in ACH. The problem: hitting FGFR1 and FGFR2 causes hyperphosphatemia and additional off-target toxicity. More studied than TYRA-300 but riskier.
TYRA-300 (Dabogratinib) — selective FGFR3 only inhibitor. First-in-class. Mouse data (https://insight.jci.org/articles/view/189307) showed significant increases in femur length (+3.7–5%), tibia length (+3.75–6%), and improved skeletal proportionality even in wild-type (normal) mice — not just ACH models. This is huge because it suggests benefit even without a pathological FGFR3 mutation. Spares FGFR1/2/4 so avoids the phosphate toxicity of infigratinib. Main issues: no human height trial data yet, very difficult to verify product purity from gray market sources, expensive.
Erdafitinib — pan-FGFR1-4 inhibitor, most potent but least selective. One case study showed extreme height velocity in a child on it for cancer treatment but also caused rapid overgrowth, kyphoscoliosis, and spinal deformities (https://www.sciencedirect.com/science/article/pii/S2405844024069184). Mechanism is proven but risk profile is the worst of the group. Not recommended.
Loxo-435 — highly selective FGFR3 inhibitor from Lilly. Promising alongside TYRA-300 but even less data available.
Vosoritide — CNP analog, works downstream of FGFR3 by raising cGMP and inhibiting the MAPK/ERK pathway rather than blocking the receptor directly. FDA approved for achondroplasia. RCT (https://www.nejm.org/doi/full/10.1056/NEJMoa1813446) showed +1.57 cm/year extra growth velocity vs placebo. Safer mechanism but weaker effect than direct FGFR3 blockade and degrades very fast requiring careful storage and daily injection. Expensive.
Honest reality check: Most FGFR compounds on the gray market are unverifiable. There are essentially no reputable lab tests confirming that what is sold as TYRA-300 or infigratinib actually contains what is claimed. For most people optimizing GH + letrozole will outperform spending money on potentially bunk FGFR compounds. TYRA-300 is worth pursuing only if you can verify pharmaceutical grade product.
Part 7 — AAS: The Double-Edged Sword
Complicated territory. AAS can both help and hurt height depending on what you use and when.
The problem with most AAS: When any androgen enters the bloodstream it reaches growth plate chondrocytes and binds directly to androgen receptors. These receptors accelerate terminal differentiation — telling chondrocytes to stop dividing and mature into bone faster. This happens regardless of dose. There is no low enough dose that completely avoids this effect. Aromatizable androgens compound this by also converting to estrogen, advancing bone age rapidly.
Halotestin (Fluoxymesterone) @ 2.5 mg/day — the most defensible option:Non-aromatizing. Cannot convert to estrogen. Provides direct AR stimulus at the growth plate, upregulating local IGF-1 receptor expression and making chondrocytes hypersensitive to the GH signal. Provides a pubertal growth stimulus without triggering the estrogen-mediated fusion pathway. The 1993 Moore study (https://pubmed.ncbi.nlm.nih.gov/8464656/) showed low-dose Halotestin in boys with growth delays resulted in final height +6.1 cm above predicted genetic baseline, with bone age advancing less than growth velocity. Keep cycles short — Halotestin is significantly hepatotoxic. Run TUDCA mandatory. Do not exceed 2.5 mg/day for height purposes.
Anavar (Oxandrolone) @ 2.5–5 mg/day:Mildest of the three. Has some pediatric ISS data. Low aromatization rate and reduces aromatizable substrate via negative feedback on HPTA. One study (https://www.jpeds.com/article/S0022-3476(71)80204-4/fulltext) showed increased height velocity but also accelerated skeletal age — some children in the trial lost 1.5–7.5 cm of predicted adult height. The velocity increase may not translate to better final height. More evidence than Halotestin but less favorable risk/reward for pure height purposes.
Winstrol (Stanozolol):Animal data (https://pubmed.ncbi.nlm.nih.gov/21823523/) shows direct effects on growth plate chondrocytes via estrogen receptor pathways. Less data than the other two. Not a first choice for height.
Masteron, Primobolan: Non-aromatizing, mild. Less data for height specifically but lower risk profile than Halotestin. May be useful for androgenic stimulus with lower hepatotoxicity.
Bottom line: If you use any AAS on a height protocol use the lowest effective dose of a non-aromatizing compound and stack mandatorily with an AI. Never use testosterone or aromatizable androgens without an AI. Monitor bone age every 4–6 months. The younger you are the more conservative you need to be.
Part 8 — Advanced Compounds
KY19382 — Wnt/β-catenin Reactivation:Small molecule CXXC5-DVL inhibitor. By disrupting the CXXC5-Dvl interaction it stabilizes nuclear β-catenin and reactivates Wnt signaling in the growth plate — directly reversing the senescence mechanism. Mouse data (https://pmc.ncbi.nlm.nih.gov/articles/PMC6458850/): 0.1 mg/kg daily for 10 weeks produced statistically significant tibial elongation (p<0.0005), increased proliferating chondrocytes, expanded proliferative and hypertrophic zones. Also promotes facial bone remodeling via periosteal apposition. Administration: subcutaneous injection preferred over transdermal. Caveats: all data is preclinical (mouse/cell line), no human height trials, Wnt pathway activation warrants cancer monitoring (though in cancer cell lines KY19382 showed anti-tumor effects via CDK1 suppression suggesting context-dependent behavior).
FOXO4-DRI — Senolytic Clearance:Synthetic peptide that selectively eliminates senescent cells by disrupting the FOXO4-p53 protective interaction, triggering apoptosis specifically in senescent chondrocytes. Rationale: senescent chondrocytes secrete SASP inflammatory factors (IL-6, MMPs) that create a toxic microenvironment suppressing nearby healthy chondrocytes and depleting the resting zone stem cell pool. Clearing them reduces this inflammatory burden and allows the remaining healthy chondrocytes to proliferate more freely. Highly theoretical for height in humans. No human data. Interesting mechanism but not something most people should approach casually.
SAG21k / Purmorphamine — Hedgehog Pathway:Small molecules that directly activate Smoothened (SMO) in the Hedgehog signaling pathway, bypassing normal Patched inhibition and activating Gli transcription factors. Effect: more epiphyseal stem cells multiply, chondrocyte columns thicken, growth plates become more active. Mouse data (https://pmc.ncbi.nlm.nih.gov/articles/PMC10506518/) showed strong enhancement of chondrogenesis. Major concern: Hedgehog pathway overactivation is strongly linked to cancer development. This is not a minor theoretical risk — sustained Hh pathway activation is a known driver of multiple cancer types. Only worth considering in very strategic short term windows if at all.
SOCS2 Inhibition:SOCS2 is a negative feedback regulator of GH signaling. It binds the phosphorylated GH receptor, promotes its degradation, and dampens STAT5 activation and IGF-1 production. Inhibiting SOCS2 removes this brake on GH signaling itself — essentially amplifying exogenous GH. Mice without SOCS2 grew 30–40% larger than wild-type with increased long-bone length (https://www.nature.com/articles/35016611). A human SOCS2 mutation was linked to gigantism. Risks: chronic GH/IGF-1 hypersignaling causes insulin resistance, potential organ enlargement, and IGF-1 is mitogenic meaning cancer risk with chronic elevation.
SCO-240 — Endogenous GH Amplification:Oral SSTR5 antagonist. Somatostatin normally inhibits GH release by binding SSTR5 on pituitary somatotrophs. SCO-240 blocks this, allowing the pituitary to release more GH in a physiological pulsatile pattern without affecting other pituitary hormones. Phase 1 data (https://pubmed.ncbi.nlm.nih.gov/38549435/) showed robust dose-dependent GH secretion comparable to therapeutic rhGH levels. Advantage over injected GH: mimics natural pulsatile pattern more closely. Disadvantages: only Phase 1 adult data, no height efficacy data in children yet, still carries standard GH excess risks.
Abaloparatide / Teriparatide — PTHrP Analogs:Both bind PTH1R, mimicking the natural PTHrP signal that keeps chondrocytes in the proliferative state and delays hypertrophic transition. Intermittent daily dosing expands proliferative and hypertrophic zones, increases chondrocyte columns, and prolongs the active growth window before senescence. Abaloparatide more closely mimics PTHrP's natural growth plate role, potentially providing a cleaner anabolic effect with less calcium/resorption side effects than teriparatide. Abalo also counteracts the bone density loss caused by aggressive AI use — making it arguably mandatory at the advanced level. Main risk: rat studies at high doses showed osteosarcoma signal. Clinical doses appear significantly below the threshold where this was observed but it is a real consideration for long term use.
Epitalon (Telomerase Activator):Aims to reduce the biological age of chondrocytes by activating telomerase and slowing cellular senescence. Highly speculative for height. The concept of keeping chondrocytes biologically younger for longer is mechanistically sound but human height data does not exist. Low risk profile. Subcutaneous injection.
Forskolin (20–50 mg/day)directly activates adenylyl cyclase, increases intracellular cAMP, and amplifies the mitogenic effects of IGF-1 and GH within chondrocytes. Makes the growth signal hit harder at the cellular level. Relatively accessible, low risk compared to everything else here. GI upset possible at higher doses.
Tamoxifen:SERM — selectively blocks estrogen receptors in some tissues. One study (https://pubmed.ncbi.nlm.nih.gov/16322179/) in 7 short pubertal boys showed tamoxifen significantly slowed skeletal maturation and increased predicted adult height by around 4 inches with no negative effects on puberty progression. However a rat study (https://pubmed.ncbi.nlm.nih.gov/18348701/) showed persistent shorter tibia, reduced cortical bone size, increased chondrocyte apoptosis, and lowered IGF-1. The evidence is too limited and contradictory to recommend over a proper AI. Stick to letrozole or anastrozole.
Part 9 — The Full Protocol Framework
Core (most evidence-backed):HGH: 6–12 IU/day, injected fasted, wait 15–30 min, then fast carbs plus aminosLetrozole: 2.5 mg/dayBerberine: 1000–1500 mg/day with mealsAcarbose: 25–50 mg with carb mealsTUDCA: 500–1000 mg/dayCitrus Bergamot: 500–1500 mg/dayOmega-3: 2–4 g EPA+DHA dailyVitamin D3/K2: 3000–5000 IU D3 plus 100–200 mcg K2 dailyThyroid monitoring (TSH, Free T3, Free T4) — T4 support if neededBlood glucose monitoring — target fasted under 100 mg/dL
Intermediate additions:TYRA-300 (selective FGFR3 inhibitor) — if verifiably pharmaceutical gradeHalotestin 2.5 mg/day — short cycles only, TUDCA mandatoryAbaloparatide — PTHrP signaling, bone density protection from AI useLantus insulin (5–10 IU baseline) — only with full glucose monitoring protocol and safety measures in placeForskolin 20–50 mg/day
Advanced (frontier territory, mostly preclinical data):KY19382 — Wnt/β-catenin reactivation, subcutaneousFOXO4-DRI — senolytic clearance of growth plateSCO-240 — endogenous GH amplificationSOCS2 inhibition — GH signaling amplification
For post-pubescent / closing plates:The aggressive multi-compound stack has diminishing returns once plates are fused. Focus shifts to: maximizing remaining open plates (clavicle, vertebral apophyses), spinal decompression, posture correction. KY19382 and abaloparatide may still be relevant for residual growth centers. Bone density protection becomes more important than growth velocity at this stage.
Part 10 — Bloodwork: Non-Negotiable
Get baseline before starting anything. Repeat at 6 weeks on cycle, then every 2–3 months.
What to check:IGF-1 — confirms GH is working and not bunk, tracks your responseEstradiol (E2) — confirms AI is working, avoid crashing below 5 pg/mLTotal + Free Testosterone — track suppression from AAS if applicableLH / FSH — track HPTA suppressionTSH, Free T3, Free T4 — thyroid health, essential on GHFasting glucose + HbA1c — metabolic health, GH insulin resistanceLipid panel (LDL, HDL, triglycerides) — AI will worsen this, monitorLiver enzymes (ALT, AST) — essential if running any oral AASBone age X-ray — every 4–6 months to track skeletal maturation vs growth velocity
If you are not monitoring bloodwork you are flying blind and have no idea if what you are doing is helping or destroying you.
Part 11 — Risks: Read This Before You Do Anything
This needs to be said clearly and seriously.
You are intervening in the most complex hormonal system in the human body during what may be its most sensitive developmental window. Most of these compounds have no safety data in healthy adolescents. The clinical data that exists is in children with diagnosed growth disorders under close medical supervision with regular monitoring.
Specific serious risks permanent endocrine disruption from AAS/AI misuse — HPTA suppression, infertility, hormonal dysregulation that does not fully recoverBone density loss from chronic E2 suppression — growing taller with structurally weaker bonesOrgan hypertrophy from excessive long-term GH — heart, kidneys, intestinesScoliosis and spinal deformity from aggressive FGFR inhibitionHepatotoxicity from oral AAS — Halotestin is seriously liver toxic, do not run it long termHypoglycemia from insulin — can cause seizures, brain damage, deathCancer risk from Wnt pathway agonists and Hedgehog activators — theoretical but real pathwaysUsing unverified gray market compounds that may be entirely bunk or contaminated with unknown substancesPsychological dependence on external hormonal manipulationBrain development effects from E2 suppression in adolescence — genuinely underresearched
The honest reality: There are no guarantees. You can take everything on this list perfectly and get zero height, or get sides with no growth. How your body responds is heavily genetic. No verified hyper-responder exists in the community. Someone who follows this thread may get 6 cm of extra height. Someone else might get organ issues and nothing else.
If you are a minor considering any of this: at minimum do this with regular bloodwork and ideally with a doctor who understands the compounds involved.
Sources
AI + GH Clinical:https://pubmed.ncbi.nlm.nih.gov/277...om/doi/abs/10.1111/j.1651-2227.1963.tb03805.x
Estrogen and Fusion:https://www.nature.com/articles/pr19992810
CXXC5 / KY19382 / Wnt:https://pmc.ncbi.nlm.nih.gov/articl...tionhttps://pubmed.ncbi.nlm.nih.gov/30971423/
FGFR Inhibitors:https://investor.bridgebio.com/news...://pmc.ncbi.nlm.nih.gov/articles/PMC12668719/
PTHrP / Abaloparatide / Vosoritide:https://www.nejm.org/doi/full/10.1056/NEJMoa1813446
AAS:https://www.jpeds.com/article/S0022...3523/https://pubmed.ncbi.nlm.nih.gov/8464656/
Tamoxifen:https://pubmed.ncbi.nlm.nih.gov/16322179/https://pubmed.ncbi.nlm.nih.gov/18348701/
SOCS2:https://www.nature.com/articles/350...blication/linked-with-missense-mutation-SOCS2
SAG21k:https://pmc.ncbi.nlm.nih.gov/articles/PMC10506518/
SCO-240:https://pubmed.ncbi.nlm.nih.gov/38549435/
This thread is for educational purposes only. Nothing here is medical advice. Everything discussed carries real risks. Do your research, get bloodwork, and if possible work with a doctor who understands what you are doing.
TAGS:
@Zagro,@Menas,@Chad ,@Typhon , @Orka rate the thread
@FutureSlayer can u take away my 90% warning high effort post
monthly costs of 12iu 5 days on and 2 days of is around 260 dollars if u find the right source thats pretty cheap if u have a job
big shout out to Choh Hao li for Hgh
youre the same shit youre no different than them
explain i may have not produced the best thread but i sitll have given info that can help people that are actually willing do osmething while their plates are open
I mean this is just a dog shit water thread that always says the same thing. I can find thousands of heightmaxxing threads and they all say the same thing6,2
Buddy this is my first guide calm downI mean this is just a dog shit water thread that always says the same thing. I can find thousands of heightmaxxing threads and they all say the same thing
Mfs wanna be niche now and start mentioning these retarded pth analogues/fgfr3 inhibs just to not sound like an echo chamber
Formatting sucks too just https://looksmax.org/account/delete
I never claimed to be knowledgeable I just wanted to post what ik atm Im gonna make some better guides in the future just ldar and i am superior to you Im 6,4 whilst ur 6,2 hate but I haven’t even started pinning yet
Sure? there's always a bigger fishBuddy this is my first guide calm down
people post all that shit almost every day
